Documente Academic
Documente Profesional
Documente Cultură
4728 Journal
Downloaded from jco.ascopubs.org on June 28, 2008 of Clinical
. For Oncology,
personal Vol No
use only. 20,other
No 24 (December
uses 15), 2002: pp 4728 – 4801
without permission.
Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved.
AUTHOR INDEX 4729
Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky Berry DA, see Guidi AJ
DS, Kim Y-C, Pitterle DM, Hyland A. Prognostic Berry DA, Broadwater G, Klein JP, Antman K, Aisner J,
Significance of Molecular Genetic Aberrations on Bitran J, Costanza M, Freytes CO, Stadtmauer E,
Chromosome Segment 11p15.5 in Non-Small-Cell Gale RP, Henderson IC, Lazarus HM, McCarthy
Lung Cancer, 1353 PL Jr, Norton L, Parnes H, Pecora A, Perry MC,
Berdzik J, see Khushalani NI Rowlings P, Spitzer G, Horowitz MM. High-Dose
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Versus Standard Chemotherapy in Metastatic
Yee GC, Biermann JS. American Society of Clin- Breast Cancer: Comparison of Cancer and Leuke-
ical Oncology Clinical Practice Guidelines: The mia Group B Trials With Data From the Autolo-
Role of Bisphosphonates in Multiple Myeloma, gous Blood and Marrow Transplant Registry, 743
3719 Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber
Beretta GD, see Cascinu S JE, Peshkin BN, Lerman C, Watson P, Lynch HT,
Berg W, see Motzer RJ Hilsenbeck SG, Rubinstein WS, Hughes KS, Par-
Berger F, see Fermé C migiani G. BRCAPRO Validation, Sensitivity of
Berger J, see Thies A Genetic Testing of BRCA1/BRCA2, and Prevalence
Berger MS, see Jennings MT of Other Breast Cancer Susceptibility Genes, 2701
Bergerat J-P, see Herbrecht R Berry DA, Parmigiani G, Rubinstein W, Watson P. In Reply
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, (correspondence), 3936
Espérou H, Socié G, Calvo F, Gluckman E, Ribaud Berthelet E, see El-Sayed S
P, Rousselot Ph, Tazi A. Hypersensitivity Pneumo- Bertolini F, see Belli F
nitis Related to Imatinib Mesylate (correspon- Bertozzi AI, see Patte C
dence), 4271 Bertucci D, see Schilsky RL
Bergman M, see Auvinen MI Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano
Bergot E, see Bergeron A L, Balzarotti M, Compasso S, Alloisio M, Parra
Bergsland EK, Venook AP. Shedding Old Paradigms: Devel- HS, Santoro A. High-Dose Chemotherapy in Poor-
oping Viruses to Treat Cancer (editorial), 2220 Prognosis Adult Small Round-Cell Tumors: Clini-
Berinstein NL. Carcinoembryonic Antigen as a Target for cal and Molecular Results From a Prospective
Therapeutic Anticancer Vaccines: A Review, 2197 Study, 2181
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Bessell EM, López-Guillermo A, Villá S, Verger E, Nomd-
Benson AB III. Phase III Study of Gemcitabine in edeu B, Petit J, Byrne P, Montserrat E, Graus F.
Combination With Fluorouracil Versus Gemcitab- Importance of Radiotherapy in the Outcome of
ine Alone in Patients With Advanced Pancreatic Patients With Primary CNS Lymphoma: An Anal-
Carcinoma: Eastern Cooperative Oncology Group ysis of the CHOD/BVAM Regimen Followed by
Trial E2297, 3270 Two Different Radiotherapy Treatments, 231
Bernard-Marty C, see Khayat D Betensky RA, Louis DN, Caimcross JG. Influence of Unrec-
Bernardo MP, see Ng AK ognized Molecular Heterogeneity on Randomized
Bernath A, see Fata F Clinical Trials, 2495
Berney DM, see Oliver RTD Beyer BCM, see Heiss MM
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS, Beyer J, see Bokemeyer C
Swiss Group for Clinical Cancer Research. Pa- see Kollmannsberger C
tients’ Estimation of Overall Treatment Burden: Beykirch MK, see Josting A
Why Not Ask the Obvious?, 65 Bezjak A, see Davis AM
Bernstein L, see Press MF see Shepherd FA
see Wickerham DL Bhagat R, see Orlowski RZ
Bernstein M, see Goorin AM Bhaskaran D, see Barakat RR
Bernstein ML, see Furman WL Bhatia S, Jenney MEM, Bogue MK, Rockwood TH, Feusner
Berruti A, see Sperone P JH, Friedman DL, Robison LL, Kane RL. The
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Minneapolis-Manchester Quality of Life Instru-
Matteis A, Nuzzo F, Giardina G, Danese S, De ment: Reliability and Validity of the Adolescent
Lena M, Lorusso V, Farris A, Sarobba MG, DeFa- Form, 4692
biani E, Bonazzi G, Castiglione F, Bumma C, Moro Bianchi F, see Scartozzi M
G, Bruzzi P, Dogliotti L. Time to Progression in Biankin AV, Morey AL, Lee S-C, Kench JG, Biankin SA,
Metastatic Breast Cancer Patients Treated With Hook HC, Head DR, Hugh TB, Sutherland RL,
Epirubicin Is Not Improved by the Addition of Henshall SM. DPC4/Smad4 Expression and Out-
Either Cisplatin or Lonidamine: Final Results of a come in Pancreatic Ductal Adenocarcinoma, 4531
Phase III Study With a Factorial Design, 4150 Biankin SA, see Biankin
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use only. AV without permission.
No other uses
Berry D, see Singletary SE Copyright © 2002 by the American Society of Clinical
Biasin E,Oncology. All rights
see Fagioli F reserved.
4734 AUTHOR INDEX
Bichakjian CK, Schwartz JL, Wang TS, Hall JM, Johnson Bleiberg H, see Louvet C
TM, Biermann JS. Melanoma Information on the Bleiberg H, Di Leo A. Mortality Associated With Irinotecan
Internet: Often Incomplete—A Public Health Op- Plus Bolus Fluorouracil/Leucovorin (correspon-
portunity?, 134 dence), 1145
Bichisao E, see Bajetta E Bleiweiss IJ, see Guidi AJ
Bickert B, see Womer RB Blessing JA, see Bloss JD
Bielack SS, see Franzius C see Muggia FM
Bielack SS, Jargens H. In Reply (correspondence), 2910 Blomgren H, see Edler D
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS,
Helmke K, Kotz R, Salzer-Kuntschik M, Werner Sood AK, Markman M, Benda J. Randomized Trial
M, Winkelmann W, Zoubek A, Jürgens H, Winkler of Cisplatin and Ifosfamide With or Without Bleo-
K, Cooperative German-Austrian-Swiss Osteosar- mycin in Squamous Carcinoma of the Cervix: A
coma Study Group. Prognostic Factors in High- Gynecologic Oncology Group Study, 1832
Grade Osteosarcoma of the Extremities or Trunk: Blumenschein GR Jr, see Herbst RS
An Analysis of 1,702 Patients Treated on Neoad- Blumgart L, see Heffernan N
juvant Cooperative Osteosarcoma Study Group Boasberg PD, see Hsueh EC
Protocols, 776 Bochner B, see Graefen M
Bierman PJ, See Vose JM Bociek G, see Weekes CD
see Weekes CD Boddy AV, see Hughes A
Biermann JS, see Berenson JR Bodnar L, see Khushalani NI
see Bichakjian CK Bodurka DC, see Eifel PJ
Biesma B, see Ardizzoni A see Strasser F
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Boerrigter L, see Crul M
Calvert AH, Gamucci T, Twelves C, Fargeot P, Boewer C, see Menssen HD
Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin Boffi R, see Galeazzi G
and Paclitaxel Versus Doxorubicin and Cyclophos- Bogue MK, see Bhatia S
phamide as First-Line Chemotherapy in Metastatic Bohlen H, see Weihrauch MR
Breast Cancer: The European Organization for Boige V, see Raymond E
Research and Treatment of Cancer 10961 Multi- Boiocchi M, see Toffoli G
center Phase III Trial, 3114 Boiron JM, see Cany L
Bigner DD, see Reardon DA see Mahon FX
Bilhou-Nabéra C, see Mahon FX Bokemeyer C, see Kersemaekers A-MF
Billett AL, see Donaldson SS see Kollmannsberger C
see LeClerc JM see Mayer F
Billups CA, see Spunt SL Bokemeyer C, Nichols CR, Droz J-P, Schmoll H-J, Horwich
Binh NC, see Love RR A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L,
Birhiray R, see Keating MJ Einhorn L, Hartmann JT. Extragonadal Germ Cell
Birkmann J, see Kaiser U Tumors of the Mediastinum and Retroperitoneum:
Birner P, Oberhuber G. Is Fluorescence In Situ Hybridization Results From an International Analysis, 1864
Really Superior to HercepTest? (correspondence), Bol CJ, see Crul M
4607 Bolla M, see Pignatti F
Bischoff HG, see Kaiser U Bomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa
Bisogno G, see Ferrari A DC, Ell PJ, Lee SM. Challenging Cases and Diag-
Bitossi R, see Berruti A nostic Dilemmas; Case 2. Pitfalls of Positron Emis-
Bitran J, see Berry DA sion Tomography for Assessing Residual Medias-
Bivens S, see Ahles TA tinal Mass After Chemotherapy for Hodgkin’s
Bivins C, see Giles FJ Disease, 3347
Bjork T, see Baselga J Bonadonna G, see Rassidakis GZ
Black PM, see Chakravarti A Bonazzi C, see Cantù MG
Blackwood MA, see Shih HA Bonazzi G, see Berruti A
Blake PR, see Kolomainen DF Bonfante V, see Rassidakis GZ
Blamey R, see Jonat W Boni C, see Scagliotti GV
Blanch J, see Prieto JM Bonner JA. Reply 2 (correspondence), 1428
Blanchon F, see Depierre A Bonneterre J, Nabholtz J-M, Budzar A, Robertson J, Thürli-
Bland KI, see Singletary SE mann B, Steinberg M, Webster A, von Euler M. In
Blanke CD, see Heinrich MC Reply
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use only.(correspondence),
No other uses without 3749
permission.
Blay JY, see Viens P Copyright © 2002 by the American Society of Clinical Oncology.
Boogerd All rights reserved.
W, see Dorresteijn LDA
AUTHOR INDEX 4735
Crawford ED. Intravesical Therapy for Superficial Cancer: Curé H, see Chevalier V
Need for More Options (editorial), 3185 Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niez-
Crawford J, see Lawrence G godzki G, Kwiatkowski F, Pezet D, Perpoint B,
see Vokes EE Coudert B, Focan C, Lévi F, Chipponi J, Chollet P.
Cremieux P, see Gabrilove JL Phase II Trial of Chronomodulated Infusion of
Cremin C, Wong N, Buzaglo K, Paradis A-J, Foulkes W. High-Dose Fluorouracil and l-Folinic Acid in Pre-
Nonovarian Pelvic Cancers in BRCA1/2 Mutation viously Untreated Patients With Metastatic Colo-
Carriers and the BRCAPRO Statistical Model (cor- rectal Cancer, 1175
respondence), 3936 Curigliano G, see De Pas T
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Curley SA, see Esnaola NF
Behm FG, Plunkett W, Raimondi SC, Pui C-H, see Vauthey J-N
Rubnitz JE, Stewart CF, Ribeiro RC. Interim Com- Curran D, see Pignatti F
parison of a Continuous Infusion Versus a Short Curran W, see Mehta MP
Daily Infusion of Cytarabine Given in Combination see Shaw E
With Cladribine for Pediatric Acute Myeloid Leu- Curtis RE, see Dores GM
kemia, 4217 Cutler C, Antin JH. In Reply (correspondence), 604
Crinò L, see Scagliotti GV Cuzick J, see Jonat W
Cripe L, see Witzig TE Cvitkovic E, see Louvet C
Crist WM, see Baker KS Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford
see Sorensen PHB E, Aronson D, Pritchard J, Chapchap P, Keeling J,
Cristofanilli M, see Esteva FJ Plaschkes J, Otte JB for the Liver Tumors Study
Critchfield GC, see Frank TS Group of the International Society of Pediatric
Crivellari D, see Spazzapan S Oncology. Hepatocellular Carcinoma in Children:
Croghan GA, see Cox LS Results of the First Prospective Study of the Inter-
Cropp GF, see Kuenen BC national Society of Pediatric Oncology Group,
Cross C, D’Amico A. In Reply (correspondence), 4129 2798
Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington Czuczman MS, see Witzig TE
R, Tomaszewski JE, Renshaw AA, Richie JP,
D’Amico AV. Impact of Race on Prostate-Specific
Antigen Outcome After Radical Prostatectomy for D
Clinically Localized Adenocarcinoma of the Pros-
tate, 2863 Dagher R, see Schwartsmann G
Crowley JJ, see Albain KS Dagnelie PC, see Agteresch HJ
Crowther D, see Radford JA Dahle R, see Sundstrøm S
Cruciani G, see Ravaioli A Daidone MG, Veneroni S, Cappelletti V, Radice P, Pierotti
Crugnola M, see Cesana C MA, Younes M. Estrogen Receptor-Beta Expres-
Crul M, de Klerk GJ, Swart M, van’t Veer LJ, de Jong D, sion in Hereditary Breast Cancer (correspondence),
Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast 3752
GC, Beijnen JH, Schellens JHM. Phase I Clinical Dakhil S, see Loesch D
and Pharmacologic Study of Chronic Oral Admin- Dakhil SR, see Jatoi A
istration of the Farnesyl Protein Transferase Inhib- Dal Lago D, see Repetto L
itor R115777 in Advanced Cancer, 2726 Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W,
Cude K, see Bennett CL Rabbani F, Donat MS, Herr HW, Sogani P, de-
Cufer T, see Biganzoli L Palma D, Bajorin D. Phase I Trial of Intravesical
Culine S, see Tepper JE Gemcitabine in Bacillus Calmette-Guérin-Refrac-
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, tory Transitional-Cell Carcinoma of the Bladder,
Lortholary A, Merrouche Y, Laplanche A, Fizazi 3193
K. Development and Validation of a Prognostic Daliani D, see Pagliaro LC
Model to Predict the Length of Survival in Patients see Papandreou CN
With Carcinomas of an Unknown Primary Site, Dalle J-H, see Perel Y
4679 Dalton V, see LeClerc JM
Cummings B, see Tepper JE Dalton VK, see Lipshultz SE
Cummings SR, see Chlebowski RT Damani MN, Master V, Meng MV, Burgess C, Turek P,
Cunningham D, see Maisey N Oates RD. Postchemotherapy Ejaculatory
see Ross P Azoospermia: Fatherhood With Sperm From Testis
Cunningham Downloaded
JM, see Lindor NM
from jco.ascopubs.org Tissue
on June 28, 2008 . For personal use only.With Intracytoplasmic
No other Sperm Injection, 930
uses without permission.
Cupini S, see Falcone A Copyright © 2002 by the American Society of Clinical Oncology.
Damasio All rights reserved.
EE, see Federico M
4742 AUTHOR INDEX
D’Amico AV, see Cross CK Davis MP, Dreicer R. Revisiting Truth and Consequences:
D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. What to Do When the Patient Doesn’t Want to
Determinants of Prostate Cancer-Specific Survival Know (correspondence), 4403
After Radiation Therapy for Patients With Clini- Davis P, see Bass AJ
cally Localized Prostate Cancer, 4567 see Rizzieri DA
D’Amico AV. Predicting Prostate-Specific Antigen Recur- Davis PC, see Nachman JB
rence Established: Now, Who Will Survive? (edi- Dawes M, see Lens MB
torial), 3188 Day A, see Davis AM
Damon L, see Linker C de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik
Dan ME, see Vaishampayan U A, Hammond LA, Weiss G, Goetz A, Siu L,
Dancey J, see Freidlin B Simmons C, Jolivet J, Rowinsky EK. Troxacitab-
Dancey JE, see Brierley JD ine, an L-Stereoisomeric Nucleoside Analog, on a
Danese S, see Berruti A Five-Times-Daily Schedule: A Phase I and Phar-
Danesi R, see Falcone A macokinetic Study in Patients With Advanced
D’Angelillo RM, see Trodella L Solid Malignancies, 96
D’Angelo A, see Oliva EN de Braud F, see De Pas T
Daniell HW. Inhibition of Opioid Analgesia by Selective de Bruijn P, see Kehrer DFS
Serotonin Reuptake Inhibitors (correspondence), De Conno F, see Galeazzi G
2409 de Gast GC, see Crul M
Danielsen HE, see Sudbø J de Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard
Danish RK, see Leung W CJC, Sein J, Holtkamp MMJ, Linthorst GAM,
Dann EJ, Fineman R, Rowe JM. Tumor Lysis Syndrome Baars JW, Schornagel JH, Rodenhuis S. Reinfusion
After STI571 in Philadelphia Chromosome-Posi- of Autologous Lymphocytes With Granulocyte-
tive Acute Lymphoblastic Leukemia (correspon- Macrophage Colony-Stimulating Factor Induces
dence), 354 Rapid Recovery of CD4⫹ and CD8⫹ T Cells After
Danoff-Burg S, see Stanton AL High-Dose Chemotherapy for Metastatic Breast
Darai E, see Barranger E Cancer, 58
Darrah D, see Mitchell MS de Giacomi C, see Pizzichetta MA
Daskalakis T, see Datta RV de Graeff A, see Koedoot CG
Datta RV, Daskalakis T, Adler H, Lehman H. Unusual de Gramont A, see Louvet C
Presentations of Uncommon Tumors; Case 3. Giant de Haan RJ, see Koedoot CG
Cell Plasmacytoma Presenting as an Intraperitoneal de Haes JC, see Jonat W
Mass, 2405 de Haes JCJM, see Koedoot CG
Daugaard G, see Petersen PM de Jong D, see Crul M
Daugherty CK, Steensma DP. Overcoming Obstacles to de Jonge MJA, see Kehrer DFS
Hospice Care: An Ethical Examination of Inertia see Mathiissen RHJ
and Inaction, 2752 de Jonge MJA, Punt CJA, Sparreboom A, Planting AST,
Daugherty CK. The “Cure” for Cancer: Can the Media Peters MEWJ, van de Schraaf J, Jackman A, Smith
Report the Hope Without the Hype? (editorial), R, de Mulder PHM, Verweij J. Phase I and Phar-
3761 macologic Study of Oral ZD9331, A Novel Non-
Daus H, see Trümper L polyglutamated Thymidylate Synthase Inhibitor, in
David J, see Vasey PA Adult Patients With Solid Tumors, 1923
Davidson BR, see Brett BT de Jongh F, see Sparreboom A
Davidson N, see Douillard J-Y de Jongh FE, Verweij J, Sparreboom A. In Reply (correspon-
Davidson NE, Levine M. Breast Cancer Consensus Meetings: dence), 1144
Vive la Difference? (editorial), 1719 de Juan C, see González-Quevedo R
Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, de Kernion J, see Graefen M
Wunder JS, Chabot P, Hammond A, Benk V, Isler de Klerk GJ, see Crul M
M, Freeman C, Goddard K, Bezjak A, Kandel RA, de la Chapelle A. Microsatellite Instability Phenotype of
Sadura A, Day A, James K, Tu D, Pater J, Zee B. Tumors: Genotyping or Immunohistochemistry?
Function and Health Status Outcomes in a Ran- The Jury Is Still Out (editorial), 897
domized Trial Comparing Preoperative and Post- de Lemos M. Safety Issues of Soy Phytoestrogensin Breast
operative Radiotherapy in Extremity Soft Tissue Cancer Patients (correspondence), 3040
Sarcoma, 4472 De Lena M, see Berruti A
Davis D, see Disis ML De Lumley L, see Perel Y
Davis DW, see Herbst RS
Downloaded from jco.ascopubs.org on June 28, 2008 . ForDe Maio use
personal E, see
only.Perrone
No otherFuses without permission.
Davis KB, see Chen WY Copyright © 2002 by the American Society of DeClinical
MarinisOncology.
F, see All rights reserved.
Scagliotti GV
AUTHOR INDEX 4743
Diasio RB, see Adjei AA Cheever MA, Knutson KL, Schiffman K. Genera-
Diasio RB. An Evolving Role for Oral Fluoropyrimidine tion of T-Cell Immunity to the HER-2/neu Protein
Drugs (editorial), 894 After Active Immunization With HER-2/neu Pep-
Dı́az-Rubio E, see González-Quevedo R tide-Based Vaccines, 2624
Dicks-Mireaux C, see Owens CM Dispenzieri A, see Anderson PM
Dieckmann K, see Timmermann B see Rajkumar SV
Dieckmann K-P, see Classen J Distefano MG, see Ferrandina G
Diehl J, see Dean A DiTaranto S, see Womer RB
Diehl V, see Josting A Dittrich Ch, see van Kesteren Ch
see Sieber M Diviné M, see Fermé C
see Weihrauch MR Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian
Dieras V, see Zelek L C, Hummer A, Venkatraman E, Spriggs DR. Ret-
Dietemann A, see Iamandi C rospective Analysis of Carboplatin and Paclitaxel
Dietrich D, see Borner MM as Initial Second-Line Therapy for Recurrent Epi-
Dietrich P-Y, see Stupp R thelial Ovarian Carcinoma: Application Toward a
DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O’Day SJ, Dynamic Disease State Model of Ovarian Cancer,
Wanek LA, Stern SL, Morton DL. Enhanced Hu- 1238
moral Immune Response Correlates With Improved Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger
Disease-Free and Overall Survival in American M. Novel Artificial Neural Network for Early
Joint Committee on Cancer Stage II Melanoma Detection of Prostate Cancer, 921
Patients Receiving Adjuvant Polyvalent Vaccine, Djulbegovic B, see Rizzo JD
3242 Dmitrovsky E, see Freemantle SJ
DiGianni LM, Garber JE, Winer EP. Complementary and Do K-A, see Vauthey J-N
Alternative Medicine Use Among Women With Doelken G, see Sieber M
Breast Cancer, 34s see Sucker C
Dignam JJ, see Fisher B Dogan A, see Bomanji JB
Diller L, see Emmons K Dogliotti L, see Berruti A
Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, see Sperone P
Neuberg D, Tarbell NJ, Litman H, Garber J. Breast Döhner H, see Döhner K
Cancer Screening in Women Previously Treated for see Viardot A
Hodgkin’s Disease: A Prospective Cohort Study, Döhner J, see Fröhling S
2085 Döhner K, see Fröhling S
Dillman RO. Radiolabeled Anti-CD20 Monoclonal Antibod- Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk
ies for the Treatment of B-Cell Lymphoma, 3545 RF, Döhner H. Prognostic Significance of Partial
Dillon H, see Hersey P Tandem Duplications of the MLL Gene in Adult
Dimery I, see Osborne CK Patients 16 to 60 Years Old With Acute Myeloid
Dimitrov BD, see Oliva EN Leukemia and Normal Cytogenetics: A Study of
Dimopoulos M, see Kosmidis P the Acute Myeloid Leukemia Study Group Ulm,
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou 3254
NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika Dolan ME, see Quinn JA
D, Christakis J, Anagnostopoulos N. Treatment of Domingo-Domènech JM, see Mellado B
Waldenström’s Macroglobulinemia With Ritux- Donaldson SS, see Friedmann AM
imab, 2327 Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L,
Dinapoli R, see Shaw E Billett AL, Marcus KC, Hurwitz CA, Young JA,
Dinehart S, see Coldiron B Tarbell NJ, Weinstein HJ. VAMP and Low-Dose,
Dingee C, see Kwan W Involved-Field Radiation for Children and Adoles-
Dinh NV, see Love RR cents With Favorable, Early-Stage Hodgkin’s Dis-
Dinjens WNM, see van der Sijp JRM ease: Results of a Prospective Clinical Trial, 308
Dionne J, see Bélanger K Donat MS, see Dalbagni G
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin Donehower R, see Carducci MA
E, Capanna T, Ciardella M, Doyle-Lindrud S, Donnelly S, see Kirkwood JM
Goodwin S, Fontaine M, Adams N, Williams A, Doody D, see Harper-Wynne CL
Schwartz M, Winchell G, Wickersham K, Deutsch Doran J, see Seymour LW
P, Yao S-L. Characterization of a Novel Prostate- Dordal M, see Herbst RS
Specific Antigen-Activated Peptide-Doxorubicin Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA,
Conjugate in Patients
Downloaded With Prostate
from jco.ascopubs.org on Cancer,
June 28, 1874 Glimelius
2008 . For personal use only. No B,
otherStorm H, Pukkala
uses without E, van Leeuwen
permission.
Disis ML, Gooley TA, Copyright
Rinn K,© Davis
2002 byD,the American
PiepkornSociety
M, of Clinical Oncology. All rights
FE, Holowaty EJ,reserved.
Andersson M, Wiklund T, Joen-
AUTHOR INDEX 4745
High-Dose Chemotherapy for Patients With Ad- Finkelstein DF, see Chakravarti A
vanced Hodgkin’s Disease in Relapse or Failure Finkelstein DM, see Chakravarti A
After Initial Chemotherapy: Results of the Group Finn WG, see Mirza I
d’Études des Lymphomes de l’Adulte H89 Trial, Fioretta G, see Bouchardy C
467 Fisch M, see Bruera E
Fernández C, see González-Quevedo R see Strasser F
Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi Fisher B, see DeAngelis LM
M, Legge F, Maggiano N, Mancuso S, Capelli A, see Wickerham DL
Scambia G, Ranelletti FO. Increased Cyclooxygen- Fisher B, Bryant J, Dignam JJ, Wickerham L, Mamounas EP,
ase-2 Expression Is Associated With Chemother- Fisher ER, Margolese RG, Nesbitt L, Paik S,
apy Resistance and Poor Survival in Cervical Can- Pisanksy TM, Wolmark N. Tamoxifen, Radiation
cer Patients, 973 Therapy, or Both for Prevention of Ipsilateral
Ferranti G, see Santini D Breast Tumor Recurrence After Lumpectomy in
Ferrara JLM, see Yanik GA Women With Invasive Breast Cancers of One
Ferrari A, see Massimino M Centimeter or Less, 4141
see Spreafico F Fisher C, see Kolomainen DF
Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Fisher ER, see Fisher B
Cecchetto G, Zanetti I, Pilz T, Mattke A, Treuner J, Fisher RI. Autologous Stem-Cell Transplantation as a Com-
Carli M. Paratesticular Rhabdomyosarcoma: Re- ponent of Initial Treatment for Poor-Risk Patients
port From the Italian and German Cooperative With Aggressive Non-Hodgkin’s Lymphoma: Re-
Group, 449 solved Issues Versus Remaining Opportunity (edi-
Ferrari AC, Stone N, Stock R, Bednar M, Esseesse I, Singh torial), 4411
H, Baldwin Y, Mandeli J. 13-cis Retinoic Acid and Fishman A, see Chetrit A
Complete Androgen Blockade in Advanced Hor- Fishwick K, see Hughes A
mone-Naive Prostate Cancer Patients: Report of a Fitch TR, see Hobday TJ
Phase II Randomized Study, 538 see Jatoi A
Ferrari S, see Fagioli F Fitoussi O, see Cany L
Ferrari S, Mercuri M, Bacei G. Comment on “Prognostic Fitz CR, see Jennings MT
Factors in High-Grade Osteosarcoma of the Ex- Fizazi K, see Culine S
tremities or Trunk: An Analysis of 1,702 Patients Flaherty K, see Tao J
Treated on Neoadjuvant Cooperative Osteosarcoma Flaherty L, see Kirkwood JM
Study Group Protocols” (correspondence), 2910 Flaherty LE, see Rao UNM
Ferreira CMM, see Kashani-Sabet M see Sondak VK
Ferry D, see Ranson M see Sosman JA
Ferry DR, see Seymour LW Flamm AL, see Pentz RD
Fesen MR, see Deitcher SR Flege S, see Bielack SS
Feun L, see Agarwala SS Fleischauer AT, see Neugut AI
Feusner JH, see Bhatia S Fleisher M, see Shike M
see Katzenstein HM Fleming D, see Morkas M
Feyereislova A, see Albanell J Flesch M, see Louvet C
see Baselga J Fletcher CDM, see Brooks BJ
Fiebiger W, see Jäger G see Singer S
see Scheithauer W Fletcher JA, see Singer S
Fiere D, see Menssen HD Flinn IW, see Witzig TE
Figg WD, see Bennett CL Floeter MK, see Grem JL
see Cianfrocca M see Wilson RH
see Tan AR Flom KJ, see Press MF
Figlin RA, see Zisman A Flonn K, see Press MF
Fillet G, see Gisselbrecht C Floriani I, see Cantù MG
Fine HA. Primary Central Nervous System Lymphoma: Time Focan C, see Curé H
to Ask the Question (editorial), 4615 Fogelman I, see Jonat W
Fine R, see Mikulski SM Fogler WE, see Eder JP Jr
Finegold MJ, see Katzenstein HM Folkman J, see Eder JP Jr
Fineman R, see Dann EJ Fong Y, see Heffernan N
Fink A, see Silliman RA Fonseca R, see Rajkumar SV
Fink H, see Kröger K
Downloaded from jco.ascopubs.org on June 28, 2008 . ForFontaine M, only.
personal use see DiPaola RS without permission.
No other uses
Fink L, see Kaushal V Copyright © 2002 by the American Society of Clinical A,
Fontana Oncology. All rightsHD
see Menssen reserved.
AUTHOR INDEX 4749
Body Aromatization and Plasma Estrogen Levels in Jolivet J, Kantarjian HM. Phase II Study of Trox-
Postmenopausal Breast Cancer Patients Evaluated acitabine, a Novel Dioxolane Nucleoside Analog,
in a Randomized, Cross-Over Study, 751 in Patients With Refractory Leukemia, 656
Geissler G, see Kletzel M Gill PG, see Hersey P
Gelber RD, see Colleoni M Gill VJ, see Toso JF
see Earle CC Gille J, see Spieth K
see Goldhirsch A Gillon T, see Hudes G
see LeClerc JM Ginsberg L, see Shin DM
see Lipshultz SE Ginsberg M, see Motzer RJ
Gelber S, see Colleoni M Ginsberg RJ, see Martin J
Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, see Minsky BD
van Zomeren DM, Verweij J, Sparreboom A. Com- Gioia F, see Repetto L
parative Pharmacokinetics of Unbound Paclitaxel Giordani P, see Cascinu S
During 1- and 3-Hour Infusions, 574 Giotta F, see Vici P
Gelinas M, see El-Sayed S Giovanis P, see Ravaioli A
Geller G, see Hensley ML Giralt S, see Levine JE
Gelman RS, see Chen WY Giralt SA, see Wang XS
Gelmann EP. Molecular Biology of the Androgen Receptor, Gisselbrecht C, see Mounier N
3001 Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G,
Gelmon KA, see Van Patten CL Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin
Gemmill RM, see Bremnes RM G, Hermine O, Reyes F for the Groupe d’Etude des
Genitori L, see Massimino M Lymphomes de l’Adulte. Shortened First-Line
Georgii A, see Sieber M High-Dose Chemotherapy for Patients With Poor-
Georgoulias V, see Bafaloukos D Prognosis Aggressive Lymphoma, 2472
see Souglakos J Gitlitz BJ, see Zisman A
see Stathopoulou A Gitten R, see Socinski MA
Gerber M, see Kleinberg L Giwercman A, see Petersen PM
Gerl A, see Bokemeyer C Glanton C, see Garrison MA
see Kollmannsberger C Glantz MJ, see Mehta MP
Gershenwald JE, see Ballo MT Glaspy J, see Agarwala SS
Gerson SL. Clinical Relevance of MGMT in the Treatment of see Holmes FA
Cancer, 2388 Glatstein E, see Machtay M
Gertler SZ, see Osborne CK Glick HA, see Lee JH
Gertz MA, see Rajkumar SV Glick JH, see Goldhirsch A
Gesk S, see Viardot A see Goldhirsch A
Gessi M, see Ferrandina G Glimelius B, see Dores GM
Geyer S, see Rajkumar SV see Edler D
Gheewala P, see Narasimhan P Glisson BS, see Shin DM
Ghossein RA, see Stojadinovic A Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere
Giaccone G, see Ardizzoni A AA. Phase II Trial of Docetaxel and Cisplatin
see Kuenen B Combination Chemotherapy in Patients With Squa-
see Shepherd FA mous Cell Carcinoma of the Head and Neck, 1593
Giannarelli D, see Benedetti-Panici P Gluckman E, see Bergeron A
see Vici P see Ringdén O
Gianni AM, see Rassidakis GZ see Rocha V
Gianni L, see Baselga J Gnant M, see Jakesz R
Gianni W, see Repetto L Gockerman JP, see Bass AJ
Giantris AL, see Lipshultz SE see Rizzieri DA
Giardina G, see Berruti A Goddard K, see Davis AM
Giardini R, see Rassidakis GZ Goepfert H, see Shin DM
Gika D, see Dimopoulos MA Goessling W, McKee PH, Mayer RJ. Merkel Cell Carcinoma,
Gilbar PJ, see Denman JP 588
Gilbert FJ, see Smith IC Goetz A, see de Bono JS
Gilchrist GS, see Nachman JB Gogas H, see Bafaloukos D
Giles F, see Baker SD Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J,
Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, Schuetz
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use E,other
only. No Limuses
R, Lim H-L,
without Ong A-B, Lee H-S.
permission.
Copyright
O’Brien SM, Thomas © 2002
DA, by the M,
Andreeff American
BivinsSociety
C, of Clinical Oncology. All rights
Explaining reserved. Variability of Docetaxel
Interindividual
4752 AUTHOR INDEX
known Primary Site: A Minnie Pearl Cancer Re- Grütter R, see Kröger K
search Network Study, 1651 Grygiel JJ, see Graefen M
Greco W, see Khushalani NI Gu C-D, see Osaki T
Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Guadagnoli E, see Keating NL
Breslow NE. Pregnancy Outcome After Treatment see Silliman RA
for Wilms Tumor: A Report From the National Gualano G, see Trodella L
Wilms Tumor Study Group, 2506 Gudbjartsson DF, see Berry DA
Green DM. Use of Chest Computed Tomography for Staging Guerciolini R, see Orlowski RZ
and Treatment of Wilms’ Tumor in Children (edi- Guerra LT, see Esteva FJ
torial), 2763 Guévin R, see Klasa RJ
Green MR, see Lima CMSR Guida M, see Ridolfi R
see Vokes EE Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss
Green S, Liu P-Y, O’Sullivan J. Factorial Design Consider- IJ, Budman DR, Henderson IC, Norton L, Hayes
ations, 3424 DF. Association of Angiogenesis and Disease Out-
Green SJ, see Ellis GK come in Node-Positive Breast Cancer Patients
Greenberg ER, see Ahles TA Treated With Adjuvant Cyclophosphamide, Doxo-
Greenberg HS, see Chan JL rubicin, and Fluorouracil: A Cancer and Leukemia
Greenberg MJ, see Machtay M Group B Correlative Science Study From Protocols
Greene FL, see Singletary SE 8541/8869, 732
Greenwald P. Cancer Prevention Clinical Trials, 14s Guilmin G, see Gisselbrecht C
Greggi S, see Benedetti-Panici P Gumbrell L, see Galbraith SM
Gregurich MA, see Loesch D Gumpper KL, see Frank TS
Greil R, see Sieber M Gunderson LL, see Tepper JE
Greiner T, see Weekes CD Gunnarsson PO, see Hudes G
Greipp PR, see Rajkumar SV Guo J-Y, see Goh B-C
Grem JL, see Leonard GD Gupta M, see Thomas J
see Wilson RH Gupta RK, see DiFronzo LA
Grem JL. In Reply (correspondence), 3562 see Radford JA
Grenier J-F, see Klasa RJ Gupta SK, see Bukowski R
Gribben JG, see Howard OM Gururangan S, see Quinn JA
Gridelli C, see Scagliotti GV Gururangan S, Cavazos CM, Ashley D, Herndon JE II,
Grier HE, see Goorin AM Bruggers CS, Moghrabi A, Scarcella DL, Watral
Griffin M, see Hughes A M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase
Griffiths PD, see Lashford LS II Study of Carboplatin in Children With Progres-
Grigoraki V, see Dimopoulos MA sive Low-Grade Gliomas, 2951
Grillo-López AJ, see Witzig TE Gurwitz J, see Silliman RA
Grimm EA, see Ellerhorst JA Gutheil J, see Agarwala SS
Groeger JS, see Timoney JP Gutheil JC, see Vaughn DJ
see Vogel CL
Groen HJ, see Kehrer DFS
Gutierrez L, see Mellado B
Groene WS, see Pecora AL
Gutierrez M, Pautier P, Lhommé C. Replacement of Carbo-
Grondin SC, see Liptay MJ
platin by Oxaliplatin May Be One Solution for
Groome PA, see Huang J
Patients Treated for Ovarian Carcinoma Who Are
Gross P, see Pecora AL
Hypersensitive to Carboplatin (correspondence),
Grossbard M, see Howard OM
353
Grosshans E, see Iamandi C
Grossman SA, see Kleinberg L
Group LAME of the French Society of Pediatric Hematology
and Immunology, see Perel Y H
Groupe d’Etude des Lymphomes de l’Adulte, see Gisselbre-
cht C Haas JE, see Katzenstein HM
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson Haas N, see Hudes G
P, Yung WKA, Levin VA. Phase II Trial of Habermann TM, see Ansell SM
Temozolomide Plus the Matrix Metalloproteinase Haenggeli C-A, see Allal AS
Inhibitor, Marimastat, in Recurrent and Progressive Haese A, see Cagiannos I; Graefen M
Glioblastoma Multiforme, 1383 Haglund MM, see Quinn JA
Gruetzner KU, see Heiss MM
Downloaded from jco.ascopubs.org on June 28, 2008 . ForHahl M, use
personal see only.
Morkas M uses without permission.
No other
Grundeis M, see Kaiser UCopyright © 2002 by the American Society of ClinicalK,
Haider Oncology. All rights
see Jakesz R reserved.
4754 AUTHOR INDEX
Heideman RL, see Athale UH Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr,
Heider U, see Sezer O Meyers CA, Seabrooke LF, Khuri FR, Puduvalli
Heine B, see Fuchs IB VK, Allgood V, Fritsche HA Jr, Hinton L, Newman
Heinrich MC, see Mauro MJ RA, Crane EA, Fossella FV, Dordal M, Goodin T,
Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition Hong WK. Safety and Pharmacokinetic Effects of
of KIT Tyrosine Kinase Activity: A Novel Molec- TNP-470, an Angiogenesis Inhibitor, Combined
ular Approach to the Treatment of KIT-Positive With Paclitaxel in Patients With Solid Tumors:
Malignancies, 1692 Evidence for Activity in Non-Small-Cell Lung
Heinz J, see Josting A Cancer, 4440
Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi Herbst RS, Maddox A-M, Rothenberg ML, Small EJ, Rubin
A, Babic R, Schildberg FW, Allgayer H. Minimal EH, Baselga J, Rojo F, Hong WK, Swaisland H,
Residual Disease in Gastric Cancer: Evidence of an Averbuch SD, Ochs J, LoRusso PM. Selective Oral
Independent Prognostic Relevance of Urokinase Epidermal Growth Factor Receptor Tyrosine Ki-
Receptor Expression by Disseminated Tumor Cells nase Inhibitor ZD1839 Is Generally Well-Tolerated
in the Bone Marrow, 2005 and Has Activity in Non-Small-Cell Lung Cancer
Heisterkamp SH, see Koedoot CG and Other Solid Tumors: Results of a Phase I Trial,
Heitjan DF, see Hershman D 3815
see Grann VR Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey
see Neugut AI DJ, Charnsangavej C, O’Reilly MS, Kim H-W,
Hellenic Cooperative Oncology Group, see Kosmidis P Baker C, Roach J, Ellis LM, Rashid A, Pluda J,
Hellman R, see Shaw E Bucana C, Madden TL, Tran HT, Abbruzzese JL.
Hellstrand K, see Agarwala SS Development of Biologic Markers of Response and
Hellwig D, see Samnick S Assessment of Antiangiogenic Activity in a Clini-
Helmchen B, see Guidi AJ cal Trial of Human Recombinant Endostatin, 3804
Helmke K, see Bielack SS Herling M, see Rassidakis GZ
Henderson CI. A Rose Is No Longer a Rose (editorial), 3365 Herman T, see Kleinberg L
Henderson IC, see Berry DA Herman TS, see Vijayalaxmi
see Guidi AJ Hermine O, see Gisselbrecht C
Hennan TS, see Vijayalaxmi Herndon JE II, see Gururangan S
Henningsson A, see Friberg LE see Kornblith AB
Henry-Amar M, see Joly F see Quinn JA
Henshall SM, see Biankin AV see Reardon DA
see Graefen M see Vokes EE
Hensley M, see Barakat RR Héron JF, see Joly F
see Scheuer L Herr HW, see Dalbagni G
Hensley ML, see Dizon DS see Rabbani F
see Schuchter LM Herrmann R, see Borner MM
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren see Sieber M
M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Herrmann Z, see Menssen HD
Spriggs DR. Gemcitabine and Docetaxel in Patients Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar
With Unresectable Leiomyosarcoma: Results of a RW, McLeod R, Gill PG, Coventry BJ, McMullen
Phase II Trial, 2824 A, Dillon H, Simes RJ. Adjuvant Immunotherapy
Hérait P, see Keating MJ of Patients With High-Risk Melanoma Using Vac-
Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, cinia Viral Lysates of Melanoma: Results of a
Campos F, Villard O, Liu K-L, Natarajan-Amé S, Randomized Trial, 4181
Lutz P, Dufour P, Bergerat J-P, Candolfi E. As- Hersh E, see Agarwala SS
pergillus Galactomannan Detection in the Diagno- Hershman D, see Grann VR
sis of Invasive Aspergillosis in Cancer Patients, see Sundararajan V
1989 Hershman D, Sundararajan V, Jacobson JS, Heitjan DF,
Herbst RS, see Albanell J Neugut AI, Grann VR. Outcomes of Tamoxifen
see Pentz RD Chemoprevention for Breast Cancer in Very High-
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Risk Women: A Cost-Effectiveness Analysis, 9
Charnsangavej C, Madden T, Davis DW, McCon- Hershock D, see Machtay M
key DJ, O’Reilly MS, Ellis LM, Pluda J, Hong Herzog P, see Nachman JB
WK, Abbruzzese JL. Phase I Study of Recombinant Hess KR, see Groves MD
Human Endostatin
Downloaded in Patients With
from jco.ascopubs.org on JuneAdvanced see Herbst
28, 2008 . For personal RS No other uses without permission.
use only.
Copyright © 2002 by the American Society of
Solid Tumors, 3792 Clinical Oncology.
Hesslewood S, seeAllSeymour
rights reserved.
LW
4756 AUTHOR INDEX
of Tamoxifen and Goserelin Versus Cyclophosph- tion Chemotherapy in Primary High-Risk Brain-
amide, Methotrexate, and Fluorouracil: Evidence stem Tumors: Phase II Study CCG-9941 of the
for the Superiority of Treatment With Endocrine Children’s Cancer Group, 3431
Blockade in Premenopausal Patients With Hor- Jeong HY, see Chiou WL
mone-Responsive Breast Cancer-Austrian Breast Jett JR. Screening for Lung Cancer: No Longer a Taboo
and Colorectal Cancer Study Group Trial 5, 4621 Subject (editorial), 1959
Jakob C, see Sezer O Jewell RC, see Kruijtzer CMF
Jakobsen A, see Edler D Jhingran A, see Eifel PJ
Jakowatz JG, see Sondak VK Joensuu T, see Dores GM
Jakubowski AA, see Rizzo JD Johannessen AC, see Sudbø J
Jamal N, see Kiss TL Johnson BA, see Wang XS
James K, see Davis AM Johnson DH. “The Guard Dies, It Does Not Surrender!”
James RD, see Radford JA Progress in the Management of Small-Cell Lung
Jameson M, see Galbraith SM Cancer? (editorial), 4618
Janicek MJ, see Eder JP Jr Johnson KA, see Potosky AL
see Howard OM Johnson M, see Levine JE
Janicot H, see Depierre A Johnson ME, see Bennett CL
Janjan NA, see Esnaola NF Johnson ML, see Esnaola NF
see Pisters PWT Johnson PJ, see Chan ATC
Jankowska P, see Bomanji JB Johnson R, see Hughes A
Jansson A, Sun X-F. Bax Expression Decreases Significantly Johnson TM, see Bichakjian CK
From Primary Tumor to Metastasis in Colorectal Johnston D, see Pearcey R
Cancer, 811 Johnston P, see Allegra CJ
Janus TJ, see Carducci MA Johnston PG, see Edler D
Janvier M, see Viens P Johnston S, see Vasey PA
Janzer R, see Stupp R Jolivet J, see Bélanger K
Japan Clinical Oncology Group, see Takada M see de Bono JS
Jaques DP, see Stojadinovic A see Giles FJ
Jargens H, see Bielack SS Joly F, Héron JF, Kalusinski L, Bottet P, Brune D, Allouache
Jarnagin W, see Heffernan N N, Macé-Lesec’h J, Couëtte JE, Pény J, Henry-
Jasiewicz Y, see Laack E Amar M. Quality of Life in Long-Term Survivors
Jaspan T, see Lashford LS of Testicular Cancer: A Population-Based Case-
Jass JR, see Lindor NM Control Study, 73
Jatoi A, Loprinzi C, Windschitl H. In Reply (correspon- Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J,
dence), 2913 Namer M, Fogelman I, de Haes JC, de Matteis A,
Jatoi A, Loprinzi CL. Adenosine Triphosphate: Does It Help Stewart A, Eiermann W, Szakolczai I, Palmer M,
Cancer Patients “Get Bigger and Stronger”? (edi- Schumacher M, Geberth M, Lisboa B. Goserelin
torial), 362 Versus Cyclophosphamide, Methotrexate, and Flu-
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, orouracil as Adjuvant Therapy in Premenopausal
Mailliard JA, Pundaleeka S, Kardinal CG, Fitch Patients With Node-Positive Breast Cancer: The
TR, Krook JE, Novotny PJ, Christensen B. Dron- Zoladex Early Breast Cancer Research Association
abinol Versus Megestrol Acetate Versus Combina- Study, 4628
tion Therapy for Cancer-Associated Anorexia: A Jones C, see Shaw E
North Central Cancer Treatment Group Study, 567 Jones H, see Machtay M
Jaubert J, see Fermé C Jones RB, see Nieto Y
Jeffrey J, see Pearcey R Jones S, see O’Shaughnessy J
Jeha S, see Schover LR Jones SE, see Holmes FA
Jelinek DF, see Ansell SM see Osborne CK
Jenkins V, Fallowfield L. Can Communication Skills Train- Jones V, see Mitchell MS
ing Alter Physicians’ Beliefs and Behavior in Jordhøy MS, Kaasa S, Loge JH, Fayers P. In Reply (corre-
Clinics?, 765 spondence), 1704
Jenney MEM, see Bhatia S Jordon VC, Marrow M. Chemoprevention of Breast Cancer:
Jennings MT, Sposto R, Boyett JM, Vezina LG, Holmes E, A Model for Change (editorial), 1
Berger MS, Bruggers CS, Bruner JM, Chan K-W, Joshi U, see Bos R
Dusenbery KE, Ettinger LJ, Fitz CR, Lafond D, Josting A, see Sieber M
Mandelbaum
Downloaded DE, Massey V, McGuire
from jco.ascopubs.org W,2008
on June 28, Mc-. ForJosting
personalA,useFranklin
only. NoJ,other
Mayuses
M, without
Koch P, Beykirch MK, Heinz
permission.
Neely L, MoultonCopyright © 2002
T, Pollack IF,byShen
the American Society of Clinical Oncology.
V. Preradia- All rights
J, Rudolph reserved.
C, Diehl V, Engert A. New Prognostic
4760 AUTHOR INDEX
DM, Fisher C, Bridges JA, Blake PR, Barton DPJ, Krook JE, see Goldberg RM
Shepherd JH, Kaye SB, Gore ME. Epithelial Ovar- see Hobday TJ
ian Cancer Metastasizing to the Brain: A Late see Jatoi A
Manifestation of the Disease With an Increasing Krown SE, see Evans SR
Incidence, 982 see Cianfrocca M
Komaki R, see Minsky BD see Hwu W-J
Koo J, see Goodwin PJ Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink
Koppang HS, see Sudbø J WW, Schot M, Jewell RC, Paul EM, Schellens
Köppler H, see Kaiser U JHM. Increased Oral Bioavailability of Topotecan
Kopreski M, see Hudes G in Combination With the Breast Cancer Resistance
Korn EL, see Freidlin B Protein and P-Glycoprotein Inhibitor GF120918,
Kornblith AB, see Silverman LR 2943
Kornblith AB, Herndon JE II, Silverman LR, Demakos EP, Kruijtzer CMF, Schellens JHM, Mezger J, Scheulen ME,
Odchimar-Reissig R, Holland JF, Powell BL, De- Keilholz U, Beijnen JH, Rosing H, Mathôt RAA,
Castro C, Ellerton J, Larson RA, Schiffer CA, Marcus S, van Tinteren H, Baas P. Phase II and
Holland JC. Impact of Azacytidine on the Quality Pharmacologic Study of Weekly Oral Paclitaxel
of Life of Patients With Myelodysplastic Syndrome Plus Cyclosporine in Patients With Advanced Non-
Treated in a Randomized Phase III Trial: A Cancer Small-Cell Lung Cancer, 4508
and Leukemia Group B Study, 2441 Krych M, see Wendtner C-M
Kornek GV, see Gedlicka C Krzakowski M, see Shepherd FA
see Scheithauer W Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P,
Korst RJ, see Martin J Quijano E, Engler H, Hutchins B, Maneval DC,
Kortmann R-D, see Timmermann B Grace MJ, Fritz MA, Störkel S, Thüroff JW, Huber
Koslowsky TC, see Weihrauch MR C, Schuler M. Successful Adenovirus-Mediated
Kosmidis P, see Bafaloukos D Wild-Type p53 Gene Transfer in Patients With
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Bladder Cancer by Intravesical Vector Instillation,
Samantas E, Boukovinas J, Fountzilas G, Skarlos 957
D, Economopoulos T, Tsavdaridis D, Papakostas P, Kubista E, see Jakesz R
Bacoyiannis C, Dimopoulos M. Paclitaxel Plus Kuczyk M, see Kollmannsberger C
Carboplatin Versus Gemcitabine Plus Paclitaxel in Kuenen B, Giaccone G. In Reply (correspondence), 3042
Advanced Non-Small-Cell Lung Cancer: A Phase Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter
III Randomized Trial, 3578 R, Huisman H, Kedde MA, Noordhuis P, van der
Kotsakis A, see Stathopoulou A Vijgh WJF, Peters GJ, Cropp GF, Scigalla P,
Kottaridis PD, see Branson K Hoekman K, Pinedo HM, Giaccone G. Dose-Find-
Kotz R, see Bielack SS ing and Pharmacokinetic Study of Cisplatin, Gem-
Kourousis C, see Souglakos J citabine, and SU5416 in Patients With Solid Tu-
see Stathopoulou A mors, 1657
Kovacsovics T, see Keating MJ Kuerer HM, see Buchholz TA
Krahl D, see Kaiser U Kufe DW, see Eder JP Jr
Krailo MD, see Katzenstein HM Kugler C, see Laack E
Kraljevic SO, see Stupp R Kugler JW, see Allegra CJ
Kramar A, see Culine S see Berlin JD
Kranenbarg EK, see Marijnen CAM see Hobday TJ
Kraus D, see Osman I Kühl J, see Timmermann B
Kraus DH, see Wong RJ Kühn R, see Rödel C
Kraut E, see Nadella P Kuhn-Regnier F, see Weihrauch MR
Kretschmer L, Neumann C. Sentinel-Node Technique Will Kun L, see Donaldson SS
Change the Design of Clinical Trials in Malignant see Friedmann AM
Melanoma (correspondence), 2208 Kung F, see Furman WL
Kris M, see Ranson M Kunst PWA, Sutedja G, Golding RP, Risse E, Kardos G,
Kris MG, see Martin J Postmus PE. Unusual Pulmonary Lesions; Case 1.
Kristal AR. Diet and Trend in Prostate-Specific Antigen: A Juvenile Bronchopulmonary Fibrosarcoma, 2745
Inferences for Prostate Cancer Risk (editorial), Kuntz KM, see Esnaola NF
3570 Kuo S-H, see Yuan A
Kröger K, Grütter R, Rudofsky G, Fink H, Niebel W. Kupelian P, see Graefen M
Follow-Up After
Downloaded fromPort-a-Cath-Induced Thrombosis
jco.ascopubs.org on June 28, 2008 . ForKupelian PA,only.
personal use see No
Graefen M without permission.
other uses
(correspondence), Copyright
2605 © 2002 by the American Society of Clinical Oncology.
see Thomas J All rights reserved.
4764 AUTHOR INDEX
Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Lamar L, see Einhorn LH
Comparison of the Efficacy of Local Therapies for Lamb DJ, see Shariat SF
Localized Prostate Cancer in the Prostate-Specific Lamba J, see Goh B-C
Antigen Era: A Large Single-Institution Experience Lamborn KR, see Donaldson SS
With Radical Prostatectomy and External-Beam Lammertsma AA, see Bos R
Radiotherapy, 3376 Lamont A, see Shepherd FA
Kuperstein G, see Liede A Lamont EB, see Iwashyna TJ
Kurie JM, see Rizvi NA Landman-Parker J, see Perel Y
Kuriyama K, see Imashuku S Landoni F, see Benedetti-Panici P
Kurzawinski TR, see Brett BT Landrum MB, see Keating NL
Kusumoto M, see Sobue T see Silliman RA
Kutok JL, Aster JC. Molecular Biology of Anaplastic Lym- Lang F, see Scheithauer W
phoma Kinase-Positive Anaplastic Large-Cell Lange BJ, see Ruers TJM
Lymphoma, 3691 see Woods WG
Kuttesch JF, see Athale UH
Langenhoff BS, Oyen WJG, Jager GJ, Strijk SP, Wobbes Th,
Kuzel T, see Hinton S
Corstens FHM, Ruers TJM. Efficacy of Fluorine-
Kwan W, Jackson J, Weir LM, Dingee C, McGregor G,
18-Deoxyglucose Positron Emission Tomography
Olivotto IA. Chronic Arm Morbidity After Cura-
in Detecting Tumor Recurrence After Local Abla-
tive Breast Cancer Treatment: Prevalence and Im-
tive Therapy for Liver Metastases: A Prospective
pact on Quality of Life, 4242
Study, 4453
Kwan WH, see Chan ATC
Langer AS, see Winer EP
Kwasny W, see Jakesz R
Kwiatkowski F, see Curé H Langer W, see Keating MJ
Kwok AKH, see Hon C Lanza E, see Shike M
Kwong R, see Leighl NB Laplanche A, see Culine S
Kwong YL, see Chim CS see Patte C
Kyle RA, see Berenson JR Laplante S, see Klasa RJ
see Rajkumar SV Larkin JMG, see Kolomainen DF
Larocca LM, see Teofili L
Laroia ST, Potti A, Rabbani M, Mehdi SA, Koch M. Unusual
Pulmonary Lesions; Case 3. Pulmonary Vein
L
Leiomyosarcoma Presenting as a Left Atrial Mass,
2749
Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler Larson RA, see Kornblith AB
L, Brümmer J, Schumacher U, Hossfeld DK. Ex- see Morrison VA
pression of CEACAM1 in Adenocarcinoma of the see Silverman LR
Lung: A Factor of Independent Prognostic Signif-
Larson SM, see Wong RJ
icance, 4279
Lash TL, see Silliman RA
Labianca R, see Cascinu S
Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D,
see Ridolfi R
Griffiths PD, Doz F, Ironside J, Robson K, Hobson
Labopin M, see Ringdén O
R, Dugan M, Pearson ADJ, Vassal G, Frappaz D.
see Rocha V
Temozolomide in Malignant Gliomas of Child-
LaCombe MA. Radiotherapy Dose Escalation in High-Grade
hood: A United Kingdom Children’s Cancer Study
Gliomas (correspondence), 3358
Lacy MQ, see Rajkumar SV Group and French Society for Pediatric Oncology
Lafond D, see Jennings MT Intergroup Study, 4684
Lai M, see Chan ATC Lathan B, see Sieber M
Laidlaw IJ, see Harper-Wynne CL Latkany L, see Shike M
Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Lau C, see Poon RT-P
Osin PP, McGuffog L, Easton DF for the Breast Lau H, see El-Sayed S
Cancer Linkage Consortium. The Pathology of Lau WH, see Chan ATC
Familial Breast Cancer: Predictive Value of Immu- Laughlin MJ, see Rizzieri DA
nohistochemical Markers Estrogen Receptor, Pro- Laurent-Puig P, see Etienne M-C
gesterone Receptor, HER-2, and p53 in Patients Lauriola L, see Ferrandina G
With Mutations in BRCA1 and BRCA2, 2310 see Piantelli M
Lam CCK, see Chim CS Lauwers GY, see Vauthey J-N
Lamagnere J-P, Y jco.ascopubs.org on June 28, 2008 . ForLawlor
see Perelfrom
Downloaded personalP,use
seeonly.
Watanabe
No other Suses without permission.
Lamaj E, see Belli F Copyright © 2002 by the American Society of Clinical Oncology.
Lawrence All rights
G, Crawford J, reserved.
Shennan F. Evaluating Neoadju-
AUTHOR INDEX 4765
vant Chemotherapy in Breast Cancer (correspon- Lee T-R, see Lee H-S
dence), 2905 Lee WR. Quality of Life After Prostate Cancer Treatment
Lazarides SN, see Esnaola NF (correspondence), 3038
Lazarovici D, see Zisman A Lee Y-C, see Yuan A
Lazarus HM, see Berry DA Leer JWH, see Marijnen CAM
Lazzari I, see Belli F Legault S, see Powles T
Leahy TL, see Carducci MA Legge F, see Ferrandina G
Lebas F-X, see Depierre A Leggett BA, see Lindor NM
Lebeau B, see Depierre A Legha SS, see Eton O
Leber B, see Keating MJ Legrand C, see Ardizzoni A
Leblanc T, see Perel Y Lehky T, see Grem JL
LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, see Wilson RH
Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz Lehman H, see Datta RV
C, Schorin M, Lipshultz SE, Declerck L, Silverman Lehman MJ, see Orlowski RZ
LB, Cohen HJ, Sallan SE. Treatment of Childhood Lehmann W, see Allal AS
Acute Lymphoblastic Leukemia: Results of Dana- Leibel SA, see Zelefsky MJ
Farber ALL Consortium Protocol 87-01, 237 Leibenhaut M, see Mehta MP
Leclerc P, see Depierre A Leichman CG, see Khushalani NI
Lederlin P, see Fermé C Leichman L, see Khushalani NI
see Gisselbrecht C Leighl NB, Shepherd FA, Goodwin PJ. In Reply (correspon-
Lee H-S, see Goh B-C dence), 3751
Lee H-S, Kim KM, Yoon J-H, Lee T-R, Suh KS, Lee KU, Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R,
Chung JW, Park JH, Kim CY. Therapeutic Efficacy Goodwin PJ. Economic Analysis of the TAX 317
of Transcatheter Arterial Chemoembolization as Trial: Docetaxel Versus Best Supportive Care as
Compared With Hepatic Resection in Hepatocellu- Second-Line Therapy of Advanced Non-Small-Cell
lar Carcinoma Patients With Compensated Liver Lung Cancer, 1344
Function in a Hepatitis B Virus-Endemic Area: A Leikauf GD, see Mohr S
Prospective Cohort Study, 4459 Leis J, see Levine JE
Lee J, see Socinski MA Leissner J, see Kuball J
Lee J-H, see Socinski MA Leitzel K, see Lipton A
Lee J-S, see Lee Jung-Hee Lemarié E, see Depierre A
Lee JE, see Ballo MT Lembersky BC, see Douillard J-Y
see Pisters PWT Lenauer A, see Scheithauer W
Lee Je-Hwan, see Lee Jung-Hee Lens MB, Dawes M. In Reply (correspondence),4121, 4123
Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-Analytic Lens MB, Dawes M. Interferon Alfa Therapy for Malignant
Model and Cost-Effectiveness Evaluation of Post- Melanoma: A Systematic Review of Randomized
mastectomy Radiation Therapy in High-Risk Pre- Controlled Trials, 1818
menopausal Breast Cancer Patients, 2713 Lenzi R, see Baile WF
Lee JJ, see Eton O see Pisters PWT
see Shin DM Leonard GD, Zhuang SH, Grem JL. Epirubicin, Cisplatin,
Lee JS, see Rizvi NA and Protracted Venous-Infusion Fluorouracil in
Lee Jung-Hee, Lee Je-Hwan, Ahn J-H, Bahng H, Kim T-W, Advanced Esophagogastric Cancer (correspon-
Kang Y-K, Lee K-H, Kim J-C, Yu C-S, Kim J-H, dence), 4124
Ahn S-D, Kim W-K, Kim S-H, Lee J-S. Random- Leonard R, see O’Shaughnessy J
ized Trial of Postoperative Adjuvant Therapy in Leone DM, see Timoney JP
Stage II and III Rectal Cancer to Define the Leone G, see Teofili L
Optimal Sequence of Chemotherapy and Radio- Leontovich O, see Lindor NM
therapy: A Preliminary Report, 1751 Leopold KA, see Vokes EE
Lee JY, see Cianfrocca M Lepage E, see Gisselbrecht C
Lee K-H, see Lee Jung-Hee Lerman C, see Berry DA
Lee KU, see Lee H-S see Schwartz MD
Lee S-C, see Biankin AV Lersch C, see Schmelz R
see Goh B-C Lertora JJL, see Rozans M
Lee SJ, see Loberiza FR Jr Lesimple T, see Culine S
see Rizzo JD Lesser G, see Kleinberg L
Lee SM, see Downloaded
Bomanji JBfrom jco.ascopubs.org on June 28, 2008 . ForLester E, use
personal seeonly.
Lima NoCMSR
other uses without permission.
Lee SW, see Chan JL Copyright © 2002 by the American Society of Clinical Oncology.
Letoublon All rights M-C
C, see Etienne reserved.
4766 AUTHOR INDEX
Martini M, see Teofili L Mauro MJ, O’Dwyer M, Heinrich MC, Druker BJ. STI571: A
Martino B, see Oliva EN Paradigm of New Agents for Cancer Therapeutics,
Martino R, see Levine JE 325
Martins H, see Shepherd FA Mavroudis D, see Souglakos J
Martone M, see Heffernan N see Stathopoulou A
Marty M, see Zelek L Mavroukakis S, see Toso JF
Marx GM, see Steer CB May JT, see Osborne CK
Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat May M, see Josting A
D. Unexpected Serious Toxicity With Chemother- Mayer F, see Kersemaekers A-MF
apy and Antiangiogenic Combinations: Time to Mayer F, Kersemaekers A-M, Oosterhuis JW, Bokemeyer C,
Take Stock! (editorial), 1446 Looijenga LHJ. In Reply (correspondence), 3928
Marymount MH, see Kletzel M Mayer RJ, see Goessling W
Masaki KH, see Rajq V see Tepper JE
Mascaro JM, see Albanell J Mazumdar M, see Dalbagni G
Masi G, see Falcone A see Motzer RJ
Maslak P, see Schwartz GK see Vuky J
Massey V, see Jennings MT Mazza E, see Massimino M
Massimino M, see Spreafico F McCabe M, see Sateren WB
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro- McCachren S, see Mikulski SM
Tess JD, Gandolo L, Riva D, Ruggiero A, Valentini McCarthy PL Jr, see Berry DA
L, Mazza E, Genitori L, Di Rocco C, Navarria P, McCarthy WH, see Hersey P
Casanova M, Ferrari A, Luksch R, Terenziani M, McCloskey E, see Powles T
Balestrini MR, Colosimo C, Fossati-Bellani F. McCluskey ER, see Deitcher SR
High Response Rate to Cisplatin/Etoposide Regi- McConkey DJ, see Herbst RS
men in Childhood Low-Grade Glioma, 4209 McDermott RS, Maher MM, Dunleavy K, O’Keane CJ, Stack
Master V, see Damani MN JP, Carney DP. Unusual Presentations of Lym-
Masters GA, see Liptay MJ phoma; Case 2. Non-Hodgkin’s Lymphoma Pre-
Masuda N, see Noura S senting as Liver Disease, 1943
Masullo L, see Buchholz TA McGowan TS, see Brierley JD
Matano E, see Scagliotti GV McGregor G, see Kwan W
Mathijssen RHJ, see Kehrer DFS McGuffog L, see Lakhani SR
see Xie R McGuigan K, see Pearson ML
Mathijssen RHJ, Loos WJ, Sparreboom A, Verweij J, Karls- McGuire EJ, see Izawa JI
son MO. In Reply (correspondence), 4609 McGuire W, see Jennings MT
Mathijssen RHJ, Verweij J, de Jonge MJA, Nooter K, Stoter McGuirt C, see Rivera E
G, Sparreboom A. Impact of Body-Size Measures McGuirt PV, see Schilsky RL
on Irinotecan Clearance: Alternative Dosing Rec- McIntyre LM, see Bepler G
ommendations, 81 McKee PH, see Goessling W
Mathôt RAA, see Kruijtzer CMF McLaughlin P, see Rassidakis GZ
see van Kesteren Ch see Sarris AH
Matsui E, see Sobue T McLaughlin PW, see Sanda MG
Matsumoto T, see Noura S see Wei JT
Matsuura N, see Noura S McLendon RE, see Quinn JA
Matthay KK, see Yanik GA see Reardon DA
Matthes S, see Nieto Y McLeod HL. Genetic Strategies to Individualize Supportive
Mattke A, see Ferrari A Care (editorial), 2765
Matulonis U, see Diller L McLeod R, see Hersey P
Mauch P, see Diller L McMillan A, see Smaletz O
Mauch PM, see Ng AK McMullen A, see Hersey P
Maughan T, see Keating MJ McNeely L, see Jennings MT
Maunsell E, Drolet M, Brisson J, Robert J, Deschênes L. McNeese MD, see Buchholz TA
Dietary Change After Breast Cancer: Extent, Pre- McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M,
dictors, and Relation With Psychological Distress, Seckl MJ, Newlands ES. Low-Risk Persistent Ges-
1017 tational Trophoblastic Disease: Outcome After Ini-
Maurer HM, see Sorensen PHB tial Treatment With Low-Dose Methotrexate and
Mauriac L, see Howell A Folinic
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use Acid
only. No From
other uses1992 to permission.
without 2000, 1838
see O’Shaughnessy J Copyright © 2002 by the American Society of Clinical Oncology.
McQuaker G, see All rights reserved.
Branson K
AUTHOR INDEX 4771
and Palliative Care Physicians Concerning Termi- Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C.
nal Sedation: A Nationwide Survey, 758 Impact of High-Dose Chemotherapy on Peripheral
Morita T, Shima Y, Adachi I. Attitudes of Japanese Physi- T-Cell Lymphomas (correspondence), 1426
cians Toward Terminal Dehydration: A Nationwide Mouridsen H, Chaudri-Ross HA. In Reply (correspondence),
Survey, 4699 877
Moriyama N, see Sobue T Moynihan TJ, see Fanale MA
Morkas M, Fleming D, Hahl M. Challenges in Oncology; Mross K, see Gelderblom H
Case 2. Radiation Recall Associated With Do- Mueller J, see Rosenberg R
cetaxel, 867 Muggia F, see Alberts DS
Moro G, see Berruti A Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II Trial
Moro-Sibilot D, see Depierre A of the Pegylated Liposomal Doxorubicin in Previ-
Morra E, see Cesana C ously Treated Metastatic Endometrial Cancer: A
Morris C, see Badros A Gynecologic Oncology Group Study, 2360
see Howell A Mullan BP, see Anderson PM
see Osborne CK Mullani NA, see Herbst RS
see Ranson M Muller MJ, see Detmar SB
Morris CG, see Mendenhall WM Müller P, see Kaiser U
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Muller RJ, see Timoney JP
Appelbaum FR, Hines JD, Shepherd L, Larson RA, Müller S, see Borner MM
Schiffer CA. Therapy-Related Myeloid Leukemias Multani P, see Witzig TE
Are Observed in Patients With Chronic Lympho- Multani PS, see Witzig TE
cytic Leukemia After Treatment With Fludarabine Mundy GR. Bisphosphonates and Tumor Burden (editorial),
and Chlorambucil: Results of an Intergroup Study, 3191
Cancer and Leukemia Group B 9011, 3878 Munier S, see Carmichael J
Morrissey LH, see Greco FA Munker R, see Sieber M
see Hainsworth JD Murace R, see Santini D
Morrow M, see Singletary SE Murgo AJ, see Tan AR
Morton DL, see DiFronzo LA Muriel AC, see Rauch PK
see Hsueh EC Murphy BA, see Glisson BS
Morton KE, see Toso JF see Motzer RJ
Morton RF, see Goldberg RM Murphy M, see Osoba D
Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, see Seidman A
Gameiro P, Gandini D, Prentice HG, Goldstone A, see Vogel CL
Hoffbrand AV, Foroni L. Minimal Residual Dis- Murray JL, see Esteva FJ
ease Tests Provide an Independent Predictor of Murray PL, see Ranson M
Clinical Outcome in Adult Acute Lymphoblastic Musi M. Lack of Adherence With the Analgesic Regimen:
Leukemia, 1094 The Cancer Patients’ Perspective on a Two-Sided
Moschel RC, see Quinn JA Problem (correspondence), 2907
Mutchnick S, see Sepucha KR
Moser C, see Trümper L
Myeloma Ibandronate Study Group, see Menssen HD
Mota A, see Duenas-Gonzalez A
Myers J, see Shin DM
Motosue AM, see Spunt SL
Mylonakis N, see Kosmidis P
Mott LA, see Ahles TA
Motzer RJ, see Vuky J
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M,
Reuter V. Treatment Outcome and Survival Asso- N
ciated With Metastatic Renal Cell Carcinoma of
Non-Clear-Cell Histology, 2376 Nabholtz J-M, see Bonneterre J
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Nabid A, see El-Sayed S
Interferon-Alfa as a Comparative Treatment for Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL,
Clinical Trials of New Therapies Against Ad- Thomson J, Kadin ME, Pattengale P, Davis PC,
vanced Renal Cell Carcinoma, 289 Hutchinson RJ, White K. Randomized Comparison
Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, of Low-Dose Involved-Field Radiotherapy and No
Bacik J, Mazumdar M. Phase II Trial of Thalido- Radiotherapy for Children With Hodgkin’s Disease
mide for Patients With Advanced Renal Cell Car- Who Achieve a Complete Response to Chemother-
cinoma, 302 apy, 3765
Moulton T, see Jennings MT
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use see
Nadali G-P, only.Rassidakis
No other usesGZwithout permission.
Mounier N, see Fermé C Copyright © 2002 by the American Society of Clinical Oncology.
Nadella P, Shapiro All V,
rights reserved.GA, Hauger M, Erdal S,
Otterson
4774 AUTHOR INDEX
Germ Cell Cancer Treatment Response (correspon- Mucosa-Associated Lymphoid Tissue Lymphoma
dence), 3928 of the Bladder After Antibiotic Therapy (corre-
Oliver T, see Warde P spondence), 882
Oliverio G, see Ravaioli A O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub
Olivotto IA, see Kwan W J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y,
see Van Patten CL Mauriac L, Twelves C, Van Hazel G, Verma S,
see Weir L Leonard R. Superior Survival With Capecitabine
Ollila DW, see Hsueh EC Plus Docetaxel Combination Therapy in Anthracy-
O’Neil JD, see Pecora AL cline-Pretreated Patients With Advanced Breast
O’Neill A, see Kleinberg L Cancer: Phase III Trial Results, 2812
O’Neill B, see Shaw E O’Shaughnessy JA, see Holmes FA
O’Neill V, see Vasey PA Osin PP, see Lakhani SR
Oneschuk D, see Watanabe S Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M,
Ong A-B, see Goh B-C Bosl G, Scher H, Shah J, Shaha A, Kraus D,
Oo TH, Aish LS, Hassoun H. Unusual Presentations of Cordon-Cardo C, Pfister DG. Alteration of p53
Lymphoma; Case 1. Sea-Blue Histiocytes in Non- Pathway in Squamous Cell Carcinoma of the Head
Hodgkin’s Lymphoma, 1942 and Neck: Impact on Treatment Outcome in Pa-
Ooi CGC, see Au WY tients Treated With Larynx Preservation Intent,
Ooi GC, see Chim CS 2980
Oosterhuis JW, see Kersemaekers A-MF Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on
see Mayer F Quality of Life of Combined Trastuzumab and
Oprea C, see Herbrecht R Chemotherapy in Women With Metastatic Breast
Order SE, Court W. When the Mirror Doesn’t Reflect It at All
Cancer, 3106
(correspondence), 1144
Österborg A, Brandberg Y, Molostova V, Iosava G,
O’Reilly E, see Schwartz GK
Abdulkadyrov K, Hedenus M, Messinger D for
O’Reilly MS, see Herbst RS
the Epoetin Beta Hematology Study Group. Ran-
O’Reilly SE, see Shenkier TN
domized, Double-Blind, Placebo-Controlled
Orel SG, see Tillman GF
Trial of Recombinant Human Erythropoietin,
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC,
Epoetin Beta, in Hematologic Malignancies,
Baldwin AS, Stahl S, Adams J, Esseltine D-L,
2486
Elliott PJ, Pien CS, Guerciolini R, Anderson JK,
Ostermann-Kraljevic S, see Stupp R
Depcik-Smith ND, Bhagat R, Lehman MJ, Novick
O’Sullivan B, see Brierley JD
SC, O’Connor OA, Soignet SL. Phase I Trial of the
see Davis AM
Proteasome Inhibitor PS-341 in Patients With Re-
O’Sullivan J, see Green S
fractory Hematologic Malignancies, 4420
Ornstein DL, see Garrison MA Otake Y, see Shoji T
O’Rourke M, see Loesch D Ott G, see Viardot A
Ortega JA, see Katzenstein HM Ottaiano A, see Perrone F
Ortmann E, Hohenberg G. In Reply (correspondence), 4130 Otte JB, see Czauderna P
Ortmann E, Hohenberg G. Treatment Side Effects; Case 1. Otterson GA, see Nadella P
Radiation Recall Phenomenon After Administra- Ottestad L, see Powles T
tion of Capecitabine, 3029 Owen RG. Extramedullary Sites of Involvement in Hema-
Osaki T, Oyama T, Gu C-D, Yamashita T, So T, Takenoyama tologic Malignancies; Case 2. Lymphocyte Mor-
M, Sugio K, Yasumoto K. Prognostic Impact of phology in Splenic Marginal Zone Lymphoma,
Micrometastatic Tumor Cells in the Lymph Nodes 342
and Bone Marrow of Patients With Completely Re- Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J,
sected Stage I Non-Small-Cell Lung Cancer, 2930 Dicks-Mireaux C. Role of Chest Computed To-
Osborne C, see Du XL mography at Diagnosis in the Management of
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come Wilms’ Tumor: A Study by the United Kingdom
S, Gertler SZ, May JT, Burton G, Dimery I, Children’s Cancer Study Group, 2768
Webster A, Morris C, Elledge R, Buzdar A. Dou- Oyama T, see Osaki T
ble-Blind, Randomized Trial Comparing the Effi- Oyen WJG, see Langenhoff BS
cacy and Tolerability of Fulvestrant Versus Anas- see Ruers TJM
trozole in Postmenopausal Women With Advanced Oza A, see Carmichael J
Breast Cancer Progressing on Prior Endocrine Ozols RF. Recurrent Ovarian Cancer: Evidence-Based Treat-
Therapy: Results
Downloaded fromofjco.ascopubs.org
a North American Trial,
on June ment
3386. For personal use
28, 2008 (editorial),
only. 1161
No other uses without permission.
Oscier D, Bramble J, HodgesCopyright
E, ©Wright
2002 byD.
theRegression
American Society
of of Clinical Oncology.
Ozyilkan All rightsSreserved.
O, see Saglam
AUTHOR INDEX 4777
Kahn KL. The Case Identification Challenge in Perry MC, see Berry DA
Measuring Quality of Cancer Care, 4353 see Vokes EE
Pecora A, see Berry DA Peshkin BN, see Berry DA
Pecora AL, Rizvi N, Cohen GL, Meropol NJ, Sterman D, see Schwartz MD
Marshall JL, Goldberg S, Gross P, O’Neil JD, Pestalozzi BC, see Borner MM
Groene WS, Roberts MS, Rabin H, Bamat MK, Pestalozzi BC. Looking at the Dying Patient: The Ferdinand
Lorence RM. Phase I Trial of Intravenous Admin- Hodler Paintings of Valentine Godé-Darel, 1948
istration of PV701, an Oncolytic Virus, in Patients Pestalozzi BC. Oxaliplatin: Bimonthly, Biweekly, or Semi-
With Advanced Solid Cancers, 2251 monthly? (correspondence), 2758
Pegg AE, see Quinn JA Peterman A, see Socinski MA
Peggs KS, Mackinnon S, Yong K. Reduced Intensity Condi- Peters A, see Laack E
tioning and Allogeneic Stem-Cell Transplantation: Peters GJ, see Kuenen BC
Determining Its Role in Multiple Myeloma (corre- Peters L, see Rischin D
spondence), 4268 Peters LJ, see Rischin D
Pegram CN, see Reardon DA Peters MEWJ, see de Jonge MJA
Peltomäki P, see Percesepe A Petersen GM, see Lindor NM
Pendyala L, see Khushalani NI Petersen JH, see Petersen PM
Penn Cancer Center Clinical Trials Group, see Machtay M Petersen PM, Giwercman A, Daugaard G, Rørth M, Petersen
Pensabene M, see Perrone F JH, Skakkebæk NE, Hansen SW, von der Maase H.
Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Ayers GD, Effect of Graded Testicular Doses of Radiotherapy
Herbst RS, Abbruzzese JL. Study of the Media’s in Patients Treated for Carcinoma-In-Situ in the
Potential Influence on Prospective Research Partic- Testis, 1537
ipants’ Understanding of and Motivations for Par- Peterson BL, see Morrison VA
ticipation in a High-Profile Phase I Trial, 3785 see Silverman LR
Pény J, see Joly F Peterson N, see Wang XS
Penz M, see Jäger G Peterson P, see Groves MD
Penza SL, see Levine JE Peterson S, see Green DM
Percesepe A, Ponz de Leon M, Peltomäki P. In Reply Petit J, see Bessell EM
(correspondence), 1706 Petros W, see Rizvi NA
Perel Y, Auvrignon A, Leblanc T, Vannier J-P, Michel G, Petros WP, see Rizzieri DA
Nelken B, Gandemer V, Schmitt C, Lamagnere J-P, Petrylak D, see Small EJ
De Lumley L, Bader-Meunier B, Couillaud G, Pettengell R, see Branson K
Schaison G, Landman-Parker J, Thuret I, Dalle J-H, Pezet D, see Curé H
Baruchel A, Leverger G for the Group LAME of see Etienne M-C
the French Society of Pediatric Hematology and Pezzella G, see Vici P
Immunology. Impact of Addition of Maintenance Pfab R, see Kaiser U
Therapy to Intensive Induction and Consolidation Pfanner E, see Falcone A
Chemotherapy for Childhood Acute Myeloblastic Pfister DG, see Chlebowski RT
Leukemia: Results of a Prospective Randomized see Osman I
Trial, LAME 89/91, 2774 see Wong RJ
Perez EA, see Loprinzi CL Pfistner B, see Sieber M
Perez EA. In Reply (correspondence), 4405 Pfreundschuh M, see Kaiser U
Pergantas N, see Stathopoulos GP see Sieber M
Perilongo G, see Czauderna P see Trümper L
Perkins G, see Buchholz TA Phan A, see Sarris AH
Perkins P, see Schwartz GK Phan S, see Mehta MP
Perkins SL, see Lones MA Phillips E, see Eder JP Jr
Perlman RM, see Liptay MJ Phillips P, see Kleinberg L
Perna A, see Oliva EN Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N,
Perotti J, see Winer EP Natoli C, Cadoni G, Lauriola L, Ranelletti FO.
Perpoint B, see Curé H Lack of Expression of Galectin-3 Is Associated
Perraki M, see Stathopoulou A With a Poor Outcome in Node-Negative Patients
Perrone F, De Maio E, Maione P, Di Maio M, Ottaiano A, With Laryngeal Squamous-Cell Carcinoma, 3850
Pensabene M, Di Lorenzo G, Lombardi AV, Gallo Pica A, see Stupp R
C. Survey of Modalities of Toxicity Assessment Piccart MJ, see Biganzoli L
andDownloaded
Reportingfrom
injco.ascopubs.org
Noncomparative Prospective
on June 28, 2008 . ForPicci P, see
personal use Fagioli
only. No F
other uses without permission.
Copyright © in
Studies of Chemotherapy 2002 by theCancer,
Breast American
52Society of Clinical
Pien CS,Oncology. All rights
see Orlowski RZreserved.
AUTHOR INDEX 4779
tuberans by Targeted Inhibition of the Platelet- Scheuer L, Kauff N, Robson M, Kelly B, Barakat R,
Derived Growth Factor Receptor (editorial), 3568 Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P,
Sayer HG, see Kollmannsberger C Norton L, Offit K. Outcome of Preventive Surgery
Saykin AJ, see Ahles TA and Screening for Breast and Ovarian Cancer in
Scadden DT, see Cianfrocca M BRCA Mutation Carriers, 1260
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Scheuer L, Kauff ND, Robson ME, Offit K. In Reply
Ricci S, Matano E, Boni C, Marangolo M, Failla G, (correspondence), 3753
Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Scheulen ME, see Kruijtzer CMF
Costanzo F, Frontini L, Tonato M. Phase III Ran- Schey S, see Branson K
domized Trial Comparing Three Platinum-Based Schiffer CA, see Kornblith AB
Doublets in Advanced Non-Small-Cell Lung Can- see Morrison VA
cer, 4285 see Silverman LR
Scambia G, see Ferrandina G Schiffman K, see Disis ML
Scappaticci FA. Mechanisms and Future Directions for An- Schildberg FW, see Heiss MM
giogenesis-Based Cancer Therapies, 3906 Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain
Scarcella DL, see Gururangan S MJ. Dose-Escalating Study of Capecitabine Plus
Scardino PT, see Cagiannos I Gemcitabine Combination Therapy in Patients
see Graefen M With Advanced Cancer, 582
Scartozzi M, see Porfiri E Schilsky RL, Levin J, West WH, Wong A, Colwell B,
Scartozzi M, Bianchi F, Rosati S, Galizia E, Antolini A, Thirlwell MP, Ansari RH, Bell WN, White RL,
Loretelli C, Piga A, Bearzi I, Cellerino R, Porfiri E. Yates BB, McGuirt PV, Pazdur R. Randomized,
Mutations of hMLH1 and hMSH2 in Patients With Open-Label, Phase III Study of a 28-Day Oral
Suspected Hereditary Nonpolyposis Colorectal Regimen of Eniluracil Plus Fluorouracil Versus
Cancer: Correlation With Microsatellite Instability Intravenous Fluorouracil Plus Leucovorin as First-
and Abnormalities of Mismatch Repair Protein Line Therapy in Patients With Metastatic/Ad-
Expression, 1203 vanced Colorectal Cancer, 1519
Schaefer UW, see Ringdén O Schläfke M, see Stein U
Schafenacker A, see Northouse LL Schlegelberger B, see Viardot A
Schaison G, see Perel Y Schlenk RF, see Döhner K
Schalk K-P, see Sieber M see Fröhling S
Schaller G, see Fuchs IB Schlesselman JJ, see Sofer M
Schaller J, see Costa L Schleucher N, see Kollmannsberger C
Schapira L. An Existential Oncologist, 2407 Schmalenberg H, see Kaiser U
Schattenberg A, see Ringdén O Schmelz R, Lersch C. Acute Oxaliplatin-Induced Peripheral-
Schatzkin A, see Shike M Nerve Hyperexcitability (correspondence), 3561
Schauenstein K, see Wölfler A Schmitt C, see Patte C
Scheinberg D, see Von Roenn JH see Perel Y
Scheithauer B, see Shaw E Schmitt M, see Harbeck N
Scheithauer W, see Gedlicka C Schmitz N, see Kaiser U
Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Schmoldt J, see Kletzel M
Fiebiger W, Gedlicka C, Schüll B, Brugger S, Schmoll H-J, see Bokemeyer C
Schneeweiss B, Lang F, Lenauer A, Depisch D. Schnall MD, see Tillman GF
Randomized Multicenter Phase II Trial of Oxali- Schneeweiss B, see Scheithauer W
platin Plus Irinotecan Versus Raltitrexed as First- Schneider KA, see Chen WY
Line Treatment in Advanced Colorectal Cancer, Schnipper L, see Eder JP Jr
165 Schoch R, see Kollmannsberger C
Schelenz C, see Kaiser R Schöder H, see Wong RJ
Schell MJ, see Socinski MA Schöffski P, see Kollmannsberger C
Schellens JHM, see Crul M Schold SC, see DeAngelis LM
see Kruijtzer CMF Scholl C, see Fröhling S
see Malingré MM Scholl T, see Frank TS
see Raymond E Schorin M, see LeClerc JM
see van Kesteren Ch Schorin MA, see Lipshultz SE
Schellens JHM, Ratain MJ. Endostatin: Are the 2 Years Up Schornagel JH, see de Gast GC
Yet? (editorial), 3758 see Detmar SB
Scher H, seeDownloaded
Osman I from jco.ascopubs.org on June 28, 2008 . ForSchot M,use
personal seeonly.
Kruijtzer CMF
No other uses without permission.
Scher HI, see Smaletz O Copyright © 2002 by the American Society of Clinical Oncology.
Schover LR, BreyAll K,
rights reserved.
Lichtin A, Lipschultz LI, Jeha S.
AUTHOR INDEX 4787
Shustik C, see Klasa RJ Simone JV. Understanding Cancer Centers (editorial), 4503
Siddiqui A, see Seiter K Singer CRJ, see Menssen HD
Siddiqui N, see Vasey PA Singer S, Rubin BP, Lux ML, Chen C-J, Demetri GD,
Siderov J. Pharmacokinetics of Irinotecan and Its Metabolites Fletcher CDM, Fletcher JA. Prognostic Value of
(correspondence), 4609 KIT Mutation Type, Mitotic Activity, and Histo-
Sidor C, see Eder JP Jr logic Subtype in Gastrointestinal Stromal Tumors,
Sidranksy D, see Cheng H-L 3898
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Singh B, see Osman I
Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Singh H, see Ferrari AC
Loeffler M, Engert A, Josting A, Wolf J, Hasen- Singhal S, see Mehta J
clever D, Franklin J, Duehmke E, Georgii A, Singletary SE, see Buchholz TA
Schalk K-P, Kirchner H, Doelken G, Munker R, Singletary SE, Allred C, Ashley P, Bassett LW, Berry D,
Koch P, Herrmann R, Greil R, Anselmo AP, Diehl Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF,
V. Rapidly Alternating COPP/ABV/IMEP Is Not Hughes LL, Hutter RVP, Morrow M, Page DL,
Superior to Conventional Alternating COPP/ Recht A, Theriault RL, Thor A, Weaver DL,
ABVD in Combination With Extended-Field Ra- Wieand HS, Green FL. Revision of the American
diotherapy in Intermediate-Stage Hodgkin’s Lym- Joint Committee on Cancer Staging System for
phoma: Final Results of the German Hodgkin’s Breast Cancer, 3628
Lymphoma Study Group Trial HD5, 476 Sinibaldi V, see Carducci MA
Siebert R, see Viardot A Sirachainan E, Kalemkerian GP. Unusual Presentations of
Siedek M, see Weihrauch MR Lung Cancer: Case 2. Adrenal Insufficiency as the
Siefker-Radtke AO, Millikan RE, Tu S-M, Moore DF Jr, Initial Manifestation of Non-Small-Cell Lung Can-
Smith TL, Williams D, Logothetis CJ. Phase III cer, 4598
Trial of Fluorouracil, Interferon Alfa-2b, and Cis- Siracusano L, see Bertuzzi A
platin Versus Methotrexate, Vinblastine, Doxoru- Sisson JC, see Yanik GA
bicin, and Cisplatin in Metastatic or Unresectable Siu L, see Bélanger K
Urothelial Cancer, 1361 see de Bono JS
Siegal GP, see Goorin AM Siu LL, see Nottage M
Siegel E, see Badros A Sivesind D, see Strasser F
Siewart J-R, see Rosenberg R Skakkebæk NE, see Petersen PM
Sigurdson ER, see Kemeny MM Skalla K, see Ahles TA
Sihvo EIT, see Auvinen MI Skarlos D, see Bafaloukos D
Siivola P, see Auvinen MI see Kosmidis P
Silberfarb PM, see Ahles TA Skelin S, see Fröhling S
Sillar RW, see Hersey P Skibber JM, see Esnaola NF
Silliman RA, see Liang W Skibowski E, see Weihrauch MR
Silliman RA, Guadagnoli E, Rakowski W, Landrum MB, Skillings JR, see Douillard J-Y
Lash TL, Wolf R, Fink A, Ganz PA, Gurwitz J, Skinner DG, see Graefen M
Borbas C, Mor V. Adjuvant Tamoxifen Prescrip- Skovlund E, see Sundstrøm S
tion in Women 65 Years and Older With Primary Skovsgaard T, see Carmichael J
Breast Cancer, 2680 Slamon DJ, see Osoba D
Silver B, see Ng AK see Press MF
Silverman LB, see LeClerc JM see Vogel CL
Silverman LR, see Kornblith AB Slattery ML, see Samowitz WS
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Slawin KM, see Shariat SF
Holland JC, Odchimar-Reissig R, Stone RM, Nel- Sleddens HFBM, see van der Sijp JRM
son D, Powell BL, DeCastro CM, Ellerton J, Sloan J. Asking the Obvious Questions Regarding Patient
Larson RA, Schiffer CA, Holland JF. Randomized Burden (editorial), 4
Controlled Trial of Azacitidine in Patients With the Sloan JA, see Adjei AA
Myelodysplastic Syndrome: A Study of the Cancer see Hobday TJ
and Leukemia Group B, 2429 see Jatoi A
Simbre VC II, see Lipshultz SE see Loprinzi CL
Simes RJ, see Hersey P Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair
Simmons C, see de Bono JS S, Cha SS, Novotny PJ, Poon MA, O’Connell MJ,
Simon D, see Mounier N Loprinzi CL. Women Experience Greater Toxicity
Simon EH, see Heiss MM With
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use Fluorouracil-Based
only. No other uses withoutChemotherapy
permission. for Colo-
Simon MB, see Ramanathan Copyright
RK © 2002 by the American Society of Clinical Oncology. All rights
rectal Cancer, reserved.
1491
4790 AUTHOR INDEX
Slosman DO, see Allal AS Lung Cancer With Low-Dose Helical Computed
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Tomography: Anti-Lung Cancer Association
Regan K, Kelly WK, Kattan MW. Nomogram for Project, 911
Overall Survival of Patients With Progressive Met- Socié G, see Bergeron A
astatic Prostate Cancer After Castration, 3972 Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S,
Small BJ, see Jacobsen PB Gitten R, Unger P, Lee J, Lee J-H, Tynan M,
Small EJ, see Herbst RS Moore M, Kies MS. Phase III Trial Comparing a
see Smaletz O Defined Duration of Therapy Versus Continuous
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak Therapy Followed by Second-Line Therapy in
D, Marshall E, Rago R, Hars V, Wilding G, Advanced-Stage IIIB/IV Non-Small-Cell Lung
Petrylak D, Vogelzang NJ. Randomized Study of Cancer, 1335
Three Different Doses of Suramin Administered Sock DE, see Kilbridge KL
With a Fixed Dosing Schedule in Patients With Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway
Advanced Prostate Cancer: Results of Intergroup MS. Risk of Positive Margins and Biochemical
0159, Cancer and Leukemia Group B 9480, 3369 Recurrence in Relation to Nerve-Sparing Radical
Small TN, see Timoney JP Prostatectomy, 1853
Smaniotto D, see Benedetti-Panici P Soft Tissue Sarcoma Committee, Representing the Childhood
Smelko B, see Kirkwood JM Oncology Group, see Sorensen PHB
Smit EF, see Kuenen BC Sogani P, see Dalbagni G
Smith A, see Barakat RR Soignet S, see Barakat RR
see Klasa RJ Soignet SL, see Orlowski RZ
see Stark D Solin LJ, see Lee JH
Smith DA, see Adjei AA see Tillman GF
Smith I, see Powles T Soloway MS, see Sofer M
Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Somerville M, see Rivera E
Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sondak VK, see Kirkwood JM
Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant see Sosman JA
Chemotherapy in Breast Cancer: Significantly En- Sondak VK, Liu P-Y, Tuthill RJ, Kempf RA, Unger JM,
hanced Response With Docetaxel, 1456 Sosman JA, Thompson JA, Weiss GR, Redman
Smith J, see Khushalani NI BG, Jakowatz JG, Noyes RD, Flaherty LE. Adju-
see Rischin D vant Immunotherapy of Resected, Intermediate-
Smith JA, see Mehta MP Thickness, Node-Negative Melanoma With an Al-
Smith M, see Sateren WB logeneic Tumor Vaccine: Overall Results of a
Smith ME, see Garrison MA Randomized Trial of the Southwest Oncology
Smith P, see Khushalani NI Group, 2058
Smith R, see de Jonge MJA Soo-Hoo W, see Womer RB
Smith SC, see Brett BT Sood AK, see Bloss JD
Smith T, see Kemeny MM Sorensen PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF,
see Neff P Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr
Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz- FG for the Soft Tissue Sarcoma Committee, Rep-
Marx RL, Buchser E, Català E, Bryce DA, Coyne resenting the Childhood Oncology Group. PAX3-
PJ, Pool GE. Randomized Clinical Trial of an FKHR and PAX7-FKHR Gene Fusions Are Prog-
Implantable Drug Delivery System Compared With nostic Indicators in Alveolar Rhabdomyosarcoma:
Comprehensive Medical Management for Refrac- A Report From the Children’s Oncology Group,
tory Cancer Pain: Impact on Pain, Drug-Related 2672
Toxicity, and Survival, 4040 Sorio R, see Toffoli G
Smith TL, see Esteva FJ Sorosky J, see Muggia FM
see Siefker-Radtke AO Soslow R, see Barakat RR
Smithson WA, see Anderson PM Sosman JA, see Sondak VK
Smuck B, see Roche K Sosman JA, Unger JM, Liu P-Y, Flaherty LE, Park MS,
Smylie M, see Shepherd FA Kempf RA, Thompson JA, Terasaki PI, Sondak
Sneige N, see Esteva FJ VK. Adjuvant Immunotherapy of Resected, Inter-
Snow P, see Djavan B mediate-Thickness, Node-Negative Melanoma
So T, see Osaki T With an Allogeneic Tumor Vaccine: Impact of
Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi HLA Class I Antigen Expression on Outcome,
T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, 2067
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use only. No other uses without permission.
Copyright
Nishiyama H, Matsui E,©Eguchi
2002 byK.
theScreening
American Society
for of Clinical Oncology.
Souglakos All rights
J, Mavroudis D,reserved.
Kakolyris S, Kourousis C, Vard-
AUTHOR INDEX 4791
akis N, Androutakis N, Agelaki S, Kalbakis K, BN, Pratt CB, Merchant TE, Pappo AS. Clinical
Tsetis D, Athanasiadis N, Samonis G, Georgoulias Features and Outcome of Initially Unresected Non-
V. Triplet Combination With Irinotecan Plus Ox- metastatic Pediatric Nonrhabdomyosarcoma Soft
aliplatin Plus Continuous-Infusion Fluorouracil and Tissue Sarcoma, 3225
Leucovorin as First-Line Treatment in Metastatic Srivastava DK, see Crews KR
Colorectal Cancer: A Multicenter Phase II Trial, see Rubnitz JE
2651 Srivastava P, see Belli F
Souhami L, see Pearcey R Staats PS, see Smith TJ
Soulières D, see Bélanger K Stack JP, see McDermott RS
Southwest Oncology Group, see Sosman JA Stadler W, see Rosner GL
Soyer HP, see Pizzichetta MA Stadler WM, see Rini BI
Spaeth PJ, see Emmenegger U Stadtmauer E, see Berry DA
Spaggiari L, see De Pas T see Rai KR
Spalding S, see Yanik GA Stahl S, see Orlowski RZ
Sparreboom A, see de Jongh FE Stalmeier PFM, see van Roosmalen MS
see Gelderblom H Stamatoullas A, see Fermé C
see Kehrer DFS Stanek M, see Nadella P
see Mathijssen RHJ Stanton AL, Danoff-Burg S, Sworowski LA, Collins CA,
see Xie R Branstetter AD, Rodriguez-Hanley A, Kirk SB,
Sparreboom A, de Jongh F, Verweij J. In Reply (correspon- Austenfeld JL. Randomized, Controlled Trial of
dence), 4270 Written Emotional Expression and Benefit Finding
Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri in Breast Cancer Patients, 4160
MD, Veronesi A, Gatti A. Nail Toxicity Related to Stark D, Kiely M, Smith A, Velikova G, House A, Selby P.
Weekly Taxanes: An Important Issue Requiring a Anxiety Disorders in Cancer Patients: Their Na-
Change in Common Toxicity Criteria Grading?, ture, Associations, and Relation to Quality of Life,
4404 3137
Specht L, see Warde P Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D,
Speers C, see Weir L Athanasiadis I, Malamos NA, Stathopoulos JG.
Sperone P, Gorzegno G, Berruti A, Familiari U, Dogliotti L. Phase II Trial of Biweekly Administration of Vi-
Reversible Pancytopenia Caused by Oral Letrozole norelbine and Gemcitabine in Pretreated Advanced
Assumption in a Patient With Recurrent Breast Breast Cancer, 37
Cancer (correspondence), 3747 Stathopoulos JG, see Stathopoulos GP
Speyer J. Cardiac Dysfunction in the Trastuzumab Clinical Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M,
Experience (editorial), 1156 Kouroussis C, Apostolaki S, Malamos N, Kakolyris
Spielmann M, see Zelek L S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V.
Spieth K, Risse J, Kaufmann R, Gille J. Challenging Cases Molecular Detection of Cytokeratin-19-Positive
and Diagnostic Dilemmas; Case 3. Positron Emis- Cells in the Peripheral Blood of Patients With
sion Tomography Scan Mimicking Lymph Node Operable Breast Cancer: Evaluation of Their Prog-
Metastases in a High-Risk Melanoma Patient, 3349 nostic Significance, 3404
Spitz D, see Markman M Stavrianeas N, see Dourakis SP
Spitzer G, see Berry DA Stea B, see Thomas R
Sposto R, see Jennings MT Stearns LJ, see Smith TJ
see Lones MA Stearns V, Hayes DF. Cooling Off Hot Flashes (editorial),
see Nachman JB 1436
Spott C, see Kollmannsberger C Steensma DP, see Daugherty CK
Spreafico F, see Massimino M Steensma DP. Why Me?, 873
Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo Steer CB, see Marx GM
GS, Collini P, Ferrari A, Polastri D, Terenziani M, Steer CB, Marx GM, Galani E, Harper PG, Khayat D. Quality
Gasparini M, Fossati-Bettani F. Intensive, Very of Life: It’s Never Too Late (editorial), 2915
Short-Term Chemotherapy for Advanced Burkitt’s Steger G, see Jakesz R
Lymphoma in Children, 2783 Stein KD, see Jacobsen PB
Spriano M, see Federico M Stein U, Jürchott K, Schläfke M, Hohenberger P. Expression
Spriggs D, see Barakat RR of Multidrug Resistance Genes MVP, MDR1, and
see Schwartz GK MRP1 Determined Sequentially Before, During,
Spriggs DR, see Dizon DS and After Hyperthermic Isolated Limb Perfusion of
see Hensley ML Softonly.
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use Tissue Sarcoma
No other and Melanoma
uses without permission.Patients, 3282
Spunt SL, Hill DA, Motosue Copyright © 2002 by
AM, Billups CA,theCain
American
AM, Society
Rao of Clinical Oncology.
Steinberg All rights reserved.
M, see Bonneterre J
4792 AUTHOR INDEX
van de Vijver MJ, see Lakhani SR van Weeren PC, see Kersemaekers A-MF
van den Bent M, see Pignatti F van Zomeren DM, see Gelderblom H
van den Berg JWO, see Agteresch HJ Vandenberg T, see Winquist E
van den Bogaard CJC, see de Gast GC Vanel D, see Aloulou S
Van der Auwera P, see Viens P Vannetzel J-M, see Zelek L
van der Groep P, see Bos R Vannier J-P, see Perel Y
van der Hage JA, van de Velde CJH. In Reply (correspon- van’t Veer LJ, see Crul M
dence), 2906 van’t Veer MB, see Dores GM
van der Hage JA, van de Velde CJH. Perioperative Chemo- Vanuytsel L, see Achten R
therapy in Patients With Node-Negative Postmeno- Vardakis N, see Souglakos J
pausal Breast Cancer (correspondence), 2210 Vargas-Chanes, see Sloan JA
van der Hoeven JJM, see Bos R Varkey JA, see Cartwright TH
van der Kwast TH, see Graefen M Vasey PA, Shulman LN, Campos S, Davis J, Gore M,
van der Sijp JRM, van Meerbeeck JPAM, Maat APWM, Johnston S, Kirn DH, O’Neill V, Siddiqui N,
Zondervan PE, Sleddens HFBM, van Geel AN, Seiden MV, Kaye SB. Phase I Trial of Intraperito-
Eggermont AMM, Dinjens WNM. Determination neal Injection of the E1B-55-kd-Gene-Deleted Ad-
of the Molecular Relationship Between Multiple enovirus ONYX-015 (dl1520) Given on Days 1
Tumors Within One Patient Is of Clinical Impor- Through 5 Every 3 Weeks in Patients With Recur-
tance, 1105 rent/Refractory Epithelial Ovarian Cancer, 1562
van der Vijgh WJF, see Kuenen BC Vassal G, see Lashford LS
van der Wall E, see Bos R Vassallo E, see Fagioli F
van der Worp E, see Nagtegaal ID Vassilakopoulos TP, see Rassidakis GZ
van Diest PJ, see Bos R Vaughn D, see Hinton S
van Geel AN, see van der Sijp JRM Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz
Van Hazel G, see O’Shaughnessy J AB. Phase II Trial of Weekly Paclitaxel in Patients
van Kesteren Ch, Mathôt RAA, Raymond E, Armand JP, With Previously Treated Advanced Urothelial Can-
Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, cer, 937
Ravic M, Wanders J, Beijnen JH, Fumoleau P, Vaughn DJ, Meadows AT. Cancer Survivorship Research:
Schellens JHM. Population Pharmacokinetics of The Best Is Yet to Come (editorial), 888
the Novel Anticancer Agent E7070 During Phase I Vauthey J-N, Lauwers GY, Esnaola NF, Do K-A, Belghiti J,
Studies: Model Building and Validation, 4065 Mirza N, Curley SA, Ellis LM, Regimbeau J-M,
van Krieken JHJM, see Nagtegaal ID Rashid A, Cleary KR, Nagorney DM. Simplified
Van Le L, see Markman M Staging for Hepatocellular Carcinoma, 1527
van Leeuwen FE, see Dores GM Vauthey JN, see Pisters PWT
see Dorresteijn LDA Vecht C, see Pignatti F
van Meerbeeck JP, see Ardizzoni A Velikova G, see Stark D
see van der Sijp JRM Veneroni S, see Daidone MG
van Mourik J, see Codrington H Venkatraman E, see Barakat RR
Van Patten CL, Gelmon KA, Olivotto IA. In Reply (corre- see Dizon DS
spondence), 3041 see Hensley ML
Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, see Osman I
Hislop TG, Templeton E, Wattie A, Prior JC. Effect Venkatraman ES, see Martin J
of Soy Phytoestrogens on Hot Flashes in Postmeno- Venook AP, see Bergsland EK
pausal Women With Breast Cancer: A Random- Venturino A, see Repetto L
ized, Controlled Clinical Trial, 1449 Verbel DA, see Smaletz O
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Vercammen E, see Littlewood TJ
Norton L, Seidman AD. Assessment of Molecular Vercelli M, see Repetto L
Markers of Clinical Sensitivity to Single-Agent Verger E, see Bessell EM
Taxane Therapy for Metastatic Breast Cancer, 2319 Vergote I, see Howell A
Van Rhee F, see Badros A Verhoef G, see Achten R
van Roosmalen MS, Verhoef LCG, Stalmeier PFM, Hooger- Verhoef LCG, see van Roosmalen MS
brugge N, van Daal WAJ. Decision Analysis of Verkooijen HM, see Bouchardy C
Prophylactic Surgery or Screening for BRCA1 Mu- Verma S, see O’Shaughnessy J
tation Carriers: A More Prominent Role for Oopho- Vernillet L, see Raymond E
rectomy, 2092 Veronesi A, see Pizzichetta MA
Van SomerenDownloaded
N, see Brett BT see Spazzapan
from jco.ascopubs.org on June 28, 2008 . For personal S other uses without permission.
use only. No
Copyright
van Tinteren H, see Kruijtzer CMF© 2002 by the American Society of Clinical Oncology.
see Toffoli G All rights reserved.
AUTHOR INDEX 4797
Downloaded from jco.ascopubs.org on June 28, 2008 . For personal use only. No other uses without permission.
Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved.